NOVEL P-SELECTIN LIGAND PROTEIN

Abstract: A novel P-selectin ligand glycoprotein in disclosed, characterized by the amino acid sequence set forth in SEQ ID NO:1 or by the amino acid sequence set forth in SEQ ID NO:3. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin-mediated intercellular adhesion are also disclosed.

Description: TITLE OF THE INVENTION NOVEL P-SELECTIN LIGAND PROTEIN BACKGROUND OF THE INVENTION The present invention relates to the field of anti inflammatory substances which act by inhibiting leukocyt adhesion to endothelial cells. More particularly, the presen invention is directed to a novel ligand for the mammalia adhesion protein known as "P-selectin." During inflammation leukocytes adhere to the vascula endothelium and enter subendothelial tissue, an interaction whic is mediated by specific binding of the selectin or LEC-CAM clas of proteins to ligands on target cells. Such selectin-mediate cellular adhesion also occurs in thrombotic disorders an parasitic diseases and may be implicated in metastatic spread o tumor cells. The selectin proteins are characterized by a N-termina lectin-like domain, an epidermal growth factor-like domain, an regions of homology to complement binding proteins. Thus fa three human selectin proteins have been identified, E-selecti (formerly ELAM-1) , L-selectin (formerly LAM-1) and P-selecti (formerly PADGEM or GMP-140) . E-selectin is induced o endothelial cells several hours after activation by cytokines, mediating the calcium-dependent interaction between neutrophils and the endothelium. L-selectin is the lymphocyte homing receptor, and P-selectin rapidly appears on the cell surface of platelets when they are activated, mediating calcium-dependent adhesion of neutrophils or monocytes to platelets. P-selectin is also found in the eibel-Palade bodies of endothelial cells; upon its release from these vesicles P-selectin mediates early binding of neutrophils to histamine-or thrombin-stimulat endothelium. Selectins are believed to mediate adhesion through specifi interactions with ligands present on the surface of target cells Generally the ligands of selectins are comprised at least in par of a carbohydrate moiety. For example, E-selectin binds t carbohydrates having the terminal structure NeuAcα(2,3) Galj8(l,4) GlcNAc—R Fuc Iα(l,3) and also to carbohydrates having the terminal structure NeuAcα(2,3) Galj5(l,3) where R =the remainder of the carbohydrate chain. Thes carbohydrates are known blood group antigens and are commonl referred to as sialylated Lewis* and sialylated Lewis 1 respectively. The presence of the sialylated Lewis x antigen alon on the surface of an endothelial cell may be sufficient t promote binding to an E-selectin expressing cell. E-selecti also binds to carbohydrates having the terminal structures HS0 3 —GaljS(1,4)GlcNAc—R HS0 3 —Gal0(l,3)GlcNAc— j and J Fucα(l,3) Fucα(l,4) As with E-selectin, each selectin appears to bind to a rang of carbohydrates with varying affinities. The strength of th selectin mediated adhesive event (binding affinity) may als depend on the density of the carbohydrate and on the density o the selectin on the cell surface. P-selectin binds to carbohydrates containing the non sialylated form of the Lewis* blood group antigen and with highe affinity to sialylated Lewis*. P-selectin may also recogniz sulfatides, which are heterogeneous 3-sulfated galactosy ceramides, isolated from myeloid and tumor cells by lipi extraction. However, the binding of cells bearing P-selectin t cells bearing P-selectin ligands is abolished when the ligand bearing cells are treated with proteases, indicating that the P selectin ligand may be a glycoprotein. Two putative glycoprotein ligands for P-selectin hav recently been identified, one of which has been partiall purified, (Moore et al., J. Cell Biol. 118, 445-456 (1992)) However, neither amino acid composition nor the amino aci sequence of these glycoproteins are disclosed. SUMMARY OF THE INVENTION In one embodiment, the present invention provides composition comprising an isolated DNA sequence encoding a P selectin ligand protein, said protein being characterized by th amino acid sequence set forth in SEQ ID NO:l from amino acid to amino acid 402. Also provided is a composition comprising a isolated DNA sequence encoding a soluble P-selectin ligan protein, said protein being characterized by the amino aci sequence set forth in SEQ ID NO:l from amino acid 1 to amino aci 310. The invention further provides a composition comprising a isolated DNA sequence encoding a mature P-selectin ligan protein, said protein being characterized by the amino aci sequence set forth in SEQ ID NO:l from amino acid 42 to amin acid 402. In another embodiment, the invention provides composition comprising an isolated DNA sequence encoding soluble mature P-selectin ligand protein, said protein bein characterized by the amino acid sequence set forth in SEQ ID NO:l from amino acid 42 to amino acid 310. In another embodiment, the invention provides a composition comprising an isolated DN sequence encoding a P-selectin ligand protein, said protein being characterized by the amino acid sequence set forth in SEQ ID NO:3. The invention further provides a composition comprising an expression vector comprising any one of the isolated D sequences of the invention, said UNA sequence being operab linked to an expression control sequence; a host cell transform with the expression vector containing any one of the D sequences described above; and a process for producing the selectin ligand protein, which comprises: (a) culturing a host cell transformed with an expressi vector containing any one of the DNA sequences of the inventi in a suitable culture medium; and (b) purifying the P-selectin ligand protein from t culture medium. In another embodiment, the invention provides a compositio comprising a protein characterized by the amino acid sequence se forth in SEQ ID NO:l from amino acid 21 to amino acid 402, sai protein being substantially free from other mammalian proteins The invention further comprises a soluble P-selectin ligan protein characterized by the amino acid sequence set forth in SE ID NO:l from amino acid 21 to amino acid 310, said protein bein substantially free from other mammalian proteins, and in anothe embodiment, the invention comprises a P-selectin ligand protei characterized by the amino acid sequence set forth in SEQ ID NO: from amino acid 1 to amino acid 402, said protein bein substantially free from other mammalian proteins. The inventio also provides a composition comprising a mature P-selectin ligan protein characterized by the amino acid sequence set forth in SE ID NO:l from amino acid 42 to amino acid 402, said protein bein substantially free from other mammalian proteins. Furthe provided is a composition comprising a soluble mature P-selecti ligand protein characterized by the amino acid sequence set fort in SEQ ID NO:l from amino acid 42 to amino acid 310, said protei being substantially free from other mammalian proteins. I another embodiment the invention provides a compositio comprising a protein characterized by the amino acid sequence se forth in SEQ ID NO:3. In yet another embodiment, the invention provides composition comprising an antibody specific for the P-selecti ligand protein. In another embodiment, the invention provides a method o identifying an inhibitor of P-selectin-mediated intercellula adhesion which comprises (a) combining a P-selectin protein with a P-selectin ligan protein characterized by an amino acid sequence selected from th group consisting of the amino acid sequence set forth in SEQ I NO:l from amino acid 1 to amino acid 402, the amino acid sequenc set forth in SEQ ID NO:l from amino acid 42 to amino acid 402, the amino acid sequence set forth in SEQ ID NO:l from amino aci 42 to amino acid 310, and the amino acid sequence set forth i SEQ ID NO:3, said combination forming a first binding mixture; (b) measuring the amount of binding between the P-selecti protein and the P-selectin ligand protein in the first bindin mixture; (c) combining a compound with the P-selectin protein an the P-selectin ligand protein to form a second binding mixture; (d) measuring the amount of binding in the second bindin mixture; and (e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture; wherein the compound is capable of inhibiting P-selectin-mediated intercellular adhesion when a decrease in the amount of binding of the second binding mixture occurs. DETAILED DESCRIPTION OF THE INVENTION The present inventors have for the first time identified and isolated a novel DNA which encodes a protein which acts as a ligand for P-selectin on human endothelial cells and platelets. The complete amino acid sequence of the P-selectin ligand protein (i.e., the mature peptide plus the leader sequence) is characterized by the amino acid sequence set forth in SEQ ID NO:l from amino acid 1 to amino acid 402. Hydrophobicity analysis and comparison with known cleavage patterns predict a signal sequence of 20 to 22 amino acids, i.e., amino acids 1 to 20 or amino acids 1 to 22 of SEQ ID NO:l. The P-selectin ligand protein contains a PACE (paired basic amino acid converting enzyme) cleavage si (-Arg-Asp-Arg-Arg-) at amino acids 38-41 of SEQ ID NO:l. T mature P-selectin ligand protein of the present invention i characterized by the amino acid sequence set forth in SEQ ID N0: from amino acid 42 to amino acid 402. A soluble form of the P selectin ligand protein is characterized by containing amin acids 21 to 310 of SEQ ID NO:l. Another soluble form of th mature P-selectin ligand protein is characterized by the amin acid sequence set forth in SEQ ID NO:l from amino acid 42 t amino acid 310. The soluble form of the P-selectin ligan protein is further characterized by being soluble in aqueou solution at room temperature. Of course, the corresponding DN sequences as set forth in SEQ ID NO:l encoding these proteins ar also included in the subject invention. The P-selectin ligand of the invention is a glycoprotei which may contain one or more of the following termina carbohydrates: NeuAcα(2,3) Gal 0(1,4) GlcNAc-R |α(l,3) FUC NeuAcα(2,3) Gal jβ(l,3) GlcNAc-R |α(l,4) Fuc Gal j8(l,4)GlcNAc-R |α(l,3) Fuc Gal 3(l,3)GlcNAc-R |α.(l,4) FUC where R= the remainder of the carbohydrate chain, which i covalently attached either directly to the P-selectin ligan protein or to a lipid moiety which is covalently attached to th P-selectin ligand protein. The P-selectin ligand glycoprotei of the invention may additionally be sulfated or otherwise post- translationally modified. As expressed in COS and CHO cells full length P-selectin ligand protein (amino acids 1 to 402 o SEQ ID NO:l or amino acids 42 to 402 of SEQ ID NO:l) is homodimeric protein having an apparent molecular of 220 kD a shown by non-reducing SDS-polyacrylamide gel electrophoresis. Three regions of the P-selectin ligand protein of SEQ I NO:l are: an extracellular domain (from about amino acid 21 t 310 of SEQ ID NO:l), a transmembrane domain (from about amin acid 311 to 332 of SEQ ID NO:l), and an intracellular cytoplasmic domain (from about amino acid 333 to 402 of SEQ I NO:l). The extracellular domain contains three consensu tripeptide sites (Asn-X-Ser/Thr) of potential N-linke glycosylation beginning at Asn residues 65, 111, and 292. Th extracellular domain further contains three potential sites o tyrosine sulfation at residues 46, 48, and 51. The regio comprised of residues 55-267 contains a high percentage o proline, serine, and threonine including a subdomain of fiftee decameric repeats of the ten amino acid consensus sequence Ala Thr/Met-Glu-Ala-Gln-Thr-Thr-X-Pro/Leu-Ala/Thr, wherein X can b either Pro, Ala, Gin, Glu, or Arg. Regions such as these ar characteristic of highly O-glycosylated proteins. COS or CHO cells co-transfected with a gene encoding the P selectin ligand protein and a gene encoding an (αl,3/l,4 fucosyltransferase (hereinafter 3/4FT) are capable of binding t CHO cells expressing P-selectin on their surface, but are no capable of binding to CHO cells which do not express P-selecti on their surface. In order to bind to P-selectin, either i purified form or expressed on the surface of CHO cells, the gen encoding the P-selectin ligand protein must be co-transfecte with the gene encoding a 3/4FT, since transfection of either gen in the absence of the other either abolishes or substantiall reduces the P-selectin binding activity. The binding of the P selectin ligand protein of the invention to P-selectin can b inhibited by EDTA or by a neutralizing monoclonal antibod specific for P-selectin. The binding of the P-selectin ligan protein of the invention to P-selectin is not inhibited by a non neutralizing monoclonal antibody specific for P-selectin or b an isotype control. These results characterize the bindi specificity of the P-selectin ligand protein of the invention For the purposes of the present invention, a protein defined as having "P-selectin ligand protein activity", i.e. variably referred to herein as a "P-selectin ligand protein", o as a "P-selectin ligand glycoprotein" or simply as a "P-selecti ligand", when it binds in a calcium-dependent manner to P selectin which is present on the surface of cells as in the CHO P-selectin binding assay of Example 4, or to P-selectin which i affixed to another surface, for example, as the chimeric F selectin-IgG7l protein of Example 4 is affixed to Petri dishes The glycosylation state of the P-selectin ligand protein o the invention was studied using a chimeric, soluble form of th P-selectin ligand protein, described in detail in Example 5(C and designated SPSL.T7. The SPSL.T7 protein produced from CO cells co-transfected with 3/4FT is extensively modified b posttranslational glycosylation, as described in detail i Example 6(C). Thus, it is believed that both N- and O-linke oligosaccharide chains, at least some of which are sialylated are present on the P-selectin ligand protein of the invention. The P-selectin ligand protein of the invention may also bin to E-selectin. Conditioned medium from COS cells which have bee co-transfected with the DNA encoding SPSL.T7 and with the DN encoding 3/4FT, when coated on wells of plastic microtite plates, causes CHO cells which express E-selectin to bind to th plates; however CHO cells which do not express E-selectin do no bind to such plates. The binding of CHO cells which express E selectin to microtiter plates coated with conditioned medium fro COS cells which have been co-transfected with the DNA encodin SPSL.T7 and with the DNA encoding 3/4FT is abolished in th presence of EDTA or of a neutralizing antibody specific for E selectin. Conditioned medium from COS cells transfected onl with the SPSL.T7 DNA does not cause binding of CHO cells whic express E-selectin when coated on wells of microtiter plates. For these reasons, the P-selectin ligand protein of the inventio is believed to be useful as an inhibitor of E-selectin-mediate intercellular adhesion in addition to P-selectin-mediate intercellular adhesion. Fragments of the P-selectin ligand protein which are capabl of interacting with P-selectin or which are capable of inhibitin P-selectin-mediated intercellular adhesion are also encompasse by the present invention. Such fragments comprise amino acid 21 to 54 of SEQ ID NO:l, a region of the P-selectin ligan protein having a low frequency of serine and threonine residues amino acids 55 to 127 of SEQ ID NO:l, having a high frequency o proline, serine, and threonine in addition to two consensu sequences for asparagine-linked glycosylation (Asn-X-Ser/Thr) another larger fragment, amino acids 128 to 267 of SEQ ID N0:1 having both a high frequency of proline, serine, and threonin and containing fifteen repeats of the following ten amino aci consensus sequence: Ala-(Thr/Met)-Glu-Ala-Gln-Thr-Thr (Pro/Arg/Gln/Ala/Glu)-(Leu/Pro)-(Ala/Thr) (smaller fragment within this large fragment may also retain the capacity t interact with P-selectin or act as inhibitors of P-selectin mediated intercellular adhesion) ; the region containing consensus sequence for asparagine-linked glycosylation an comprising amino acids 268 to 308 of SEQ ID NO:l; the hydrophobi region of the protein represented by amino acids 309 to 333 o SEQ ID NO:l; and the amphiphilic region of the P-selectin ligan protein from amino acids 334 to 402. Additional fragments ma comprise amino acid 43 to amino acid 56 of SEQ ID NO:l, with on or more sulfated tyrosines at amino acid 46, amino acid 48, and/or amino acid 51. Fragments of the P-selectin ligand protei may be in linear form or they may be cyclized using know methods, for example, as described in H.U. Saragovi, et al., Bio/Technology .10., 773-778 (1992) and in R.S. McDowell, et al., J. Amer. Chem. Soc. 114. 9245-9253 (1992) , both of which ar incorporated herein by reference. For the purposes of th present invention, all references to "P-selectin ligand protein" herein include fragments capable of binding to P-selectin. Such fragments may be fused to carrier molecules such as immunoglobulins, to increase the valency of P-selectin ligand binding sites. For example, soluble forms of the P-selectin ligand protein such as the fragment from amino acid 42 to amin acid 295 of SEQ ID NO:l may be fused through "linker" sequence to the Fc portion of an immunoglobulin. For a bivalent form o the P-selectin ligand protein, such a fusion could be to the F portion of an IgG molecule as in Example 5(D) and in SEQ ID NO:6 Other immunoglobulin isotypes may also be used to generate suc fusions. For example, a P-selectin ligand protein - IgM fusio would generate a decavalent form of the P-selectin ligand protei of the invention. As detailed in the Examples below, the P-selectin ligan protein of the invention was initially obtained using a expression cloning approach (Clark et al. U.S. 4,675,285). cDNA library was constructed from the human promyelocytic cel line HL60 (S.J. Collins, et al.. Nature 270. 347-349 (1977), ATC No. CCL 240) . This library was cotransfected into COS cells wit a DNA encoding a 3/4FT, and the cotransfectants were screened fo binding to a chimeric molecule consisting of the extracellula portion of P-selectin and the Fc portion of a human IgGγ monoclonal antibody. Cotransfectants which bound to the chimeri P-selectin were enriched for cDNAs encoding the P-selectin ligan protein. This screening process was repeated several times t enrich the plasmid population further for cDNAs encoding the P selectin ligand protein. In a second cloning stage, the enriche plasmid population was again cotransfected into COS cells wit the 3/4FT gene and screened for binding to a fluorescentl labeled CHO cell line which expressed P-selectin on the cel surface. A single cDNA clone was obtained from this approach an was designated pMT21:PL85. The pMT21:PL85 plasmid was deposited with the American Type Culture Collection on October 16, 1992 and given the accession number ATCC 69096. One novel DNA of the present invention is set forth in SEQ ID NO:l. The DNA of the present invention may encode a variety of forms of the P-selectin ligand protein. For example, in one embodiment, the DNA sequence of the invention encodes the entire P-selectin ligand protein having the amino acid sequence set forth in SEQ ID NO:l from amino acid 1 to amino acid 402. In another embodiment, the DNA sequence of the invention encodes a form of the P-selectin ligand protein which lacks the sign sequence and which is characterized by the amino acid sequen set forth in SEQ ID NO:l from amino acid 21 to amino acid 40 In yet another embodiment, the DNA sequence of the inventi encodes the mature P-selectin ligand protein characterized by t amino acid sequence set forth in SEQ ID NO:l from amino acid 4 to amino acid 402. Another embodiment of the DNA sequence of t invention encodes a soluble form of the P-selectin ligand protei characterized by the amino acid sequence set forth in SEQ ID NO: from amino acid 1 to amino acid 310. The DNA of the inventio is also embodied in a DNA sequence encoding a soluble form of th mature P-selectin ligand protein, said protein bein characterized by the amino acid sequence set forth in SEQ ID N0: from amino acid 42 to amino acid 310. The DNA of the inventio is further embodied in a DNA sequence encoding a soluble form o the P-selectin ligand protein which lacks the signal sequence said protein being characterized by the amino acid sequence se forth in SEQ ID NO:l from amino acid 21 to amino acid 310. Th DNA of the present invention is free from association with othe human DNAs and is thus characterized as an isolated DNA. A detailed above, DNAs which encode P-selectin ligand fragment which interact with P-selectin are also included in the presen invention. The expression of P-selectin ligand protein mRNA transcript has been observed in a variety of human cell lines (HL-60, THP-1 U937) and in human monocytes and polymorphonuclear leukocytes b Northern analysis using a P-selectin ligand protein cDNA probe In all of these cell lines, a major transcript of 2.5 kb wa observed. A minor species of approximately 4 kb was observed i the HL60 and U937 cell lines and in polymorphonuclear leukocytes In contrast, no P-selectin ligand mRNA expression was detecte in the human hepatoblastoma cell line HepG2. The P-selectin ligand protein of the invention is encode by a single copy gene and is not part of a multi-gene family, a determined by Southern blot analysis. The genomic form of th P-selectin ligand protein of the invention contains a larg intron of approximately 9 kb located at nucleotide 54 in the 5' untranslated region. In polymorphonuclear leukocytes a monocytes, the P-selectin ligand protein of the invention encoded by the DNA sequence set forth in SEQ ID NO:3. In th embodiment, the P-selectin ligand protein contains sixteen repe regions. The isolated DNA of the invention is corresponding also embodied in the DNA sequence set forth in SEQ ID NO:3 a is contained on plasmid pPL85R16 which was deposited with th American Type Culture Collection on October 22, 1993 and give the Accession Number ATCC . The invention also encompasses allelic variations of th isolated DNA as set forth in SEQ ID NO:l or of the isolated DN as set forth in SEQ ID NO:3, that is, naturally-occurrin alternative forms of the isolated DNA of SEQ ID NO: 1 or SEQ I NO:3 which also encode proteins having P-selectin ligan activity. Also included in the invention are isolated DNAs whic hybridize to the DNA set forth in SEQ ID NO:l or to the DNA se forth in SEQ ID NO:3 under stringent (e.g. 4xSSC at 65°C or 50 formamide and 4xSSC at 42°C) , or relaxed (4xSSC at 50°C or 30-40 formamide at 42°C) conditions, and which have P-selectin ligan protein activity. Isolated DNA sequences which encode the P selectin ligand protein but which differ from the DNA set fort in SEQ ID NO:l or from the DNA set forth in SEQ ID NO:3 by virtu of the degeneracy of the genetic code and which have P-selecti ligand protein activity are also encompassed by the presen invention. Variations in the DNA as set forth in SEQ ID N0:1 o in the DNA as set forth in SEQ ID NO:3 which are caused by poin mutations or by induced modifications which enhance the P selectin ligand activity, half-life or production level are als included in the invention. For the purposes of the presen invention all references herein to the "DNA of SEQ ID NO:l include, in addition to the specific DNA sequence set forth i SEQ ID N0:1, DNA sequences encoding the mature P-selectin ligan protein of SEQ ID NO:l; DNA sequences encoding fragments of th P-selectin ligand protein of SEQ ID N0:1 which are capable o binding to P-selectin; DNA sequences encoding soluble forms o the P-selectin ligand protein of SEQ ID N0:1; allelic variation of the DNA sequence of SEQ ID N0:1; DNAs which hybridize to th DNA sequence of SEQ ID NO:l and which encode proteins having P selectin ligand protein activity; DNAs which differ from the DN of SEQ ID NO:l by virtue of degeneracy of the genetic code; an the variations of the DNA sequence of SEQ ID NO:l set fort above. Similarly, all references to the "DNA of SEQ ID NO:3 include in addition to the specific DNA sequence set forth in SE ID NO:3, DNA sequences encoding the mature P-selectin ligan protein of SEQ ID NO:3; DNA sequences encoding fragments of th P-selectin ligand protein of SEQ ID NO:3 which are capable o binding to P-selectin; DNA sequences encoding soluble forms o the P-selectin ligand protein of SEQ ID NO:3; allelic variation of the DNA sequence of SEQ ID NO:3; DNAs which hybridize to th DNA sequence of SEQ ID NO:3 and which encode proteins having P selectin ligand protein activity; DNAs which differ from the DN of SEQ ID NO:3 by virtue of degeneracy of the genetic code; an the variations of the DNA sequence of SEQ ID NO:3 set fort above. A DNA encoding a soluble form of the P-selectin ligan protein may be prepared by expression of a modified DNA in whic the regions encoding the transmembrane and cytoplasmic domain of the P-selectin ligand protein are deleted and/or a stop codo is introduced 3' to the codon for the amino acid at the carbox terminus of the extracellular domain. For example, hydrophobicity analysis predicts that the P-selectin ligan protein set forth in SEQ ID NO:l has a transmembrane domai comprised of amino acids 311 to 332 of SEQ ID NO:l and cytoplasmic domain comprised of amino acids 333 to 402 of SEQ I NO:l. A modified DNA as described above may be made by standar molecular biology techniques, including site-directedmutagenesi methods which are known in the art or by the polymerase chai reaction using appropriate oligonucleotide primers. Methods fo producing several DNAs encoding various soluble P-selectin ligan proteins are set forth in Example 5. The isolated DNA of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al.. Nucleic Acids Res..19, 4485- 4490 (1991) , in order to produce the P-selectin ligand recombinantly. Many suitable expression control sequences ar known in the art. General methods of expressing recombinan proteins are also known and are exemplified in R. Kaufman Methods in Enzymology 185. 537-566 (1990) . As defined herei "operably linked" means enzymatically or chemically ligated t form a covalent bond between the isolated DNA of the inventio and the expression control sequence, in such a way that the P selectin ligand protein is expressed by a host cell which ha been transformed (transfected) with the ligated DNA/expressio control sequence. Several endoproteolytic enzymes are known which cleav precursor peptides at the carboxyl side of paired amino aci sequences (e.g., -Lys-Arg- and -Arg-Arg-) to yield matur proteins. Such enzymes are generally known as paired basic amin acid converting enzymes or PACE, and their use in recombinan production of mature peptides is extensively disclosed in w 92/09698 and U.S. Application Serial No. 07/885,972, both o which are incorporated herein by reference. The PACE family o enzymes are known to increase the efficiency of proteolyti processing of precursor polypeptides in recombinant host cells As mentioned above, the P-selectin ligand protein of th invention contains such a PACE cleavage site. The soluble mature P-selectin ligand protein of the presen invention may be made by a host cell which contains a DN sequence encoding any soluble P-selectin ligand protein a described herein and a DNA sequence encoding PACE as describe in WO 92/09698 and U.S. Application Serial No. 07/885,972, incorporated herein by reference, or using the DNA sequence o SEQ ID NO:5. Such a host cell may contain the DNAs as the resul of co-transformation or sequential transformation of separat expression vectors containing the soluble P-selectin ligan protein DNA and the PACE DNA, respectively. A third DNA whic encodes a 3/4FT may also be co-transformed with the DNAs encoding the P-selectin ligand protein and PACE. Alternatively, the host cell may contain the DNAs as the result of transformation of a single expression vector containing both soluble P-selectin ligand protein DNA and PACE DNA. Construction of such expression vectors is within the level of ordinary skill in molecula biology. Methods for co-transformation and transformation ar also known. Many DNA sequences encoding PACE are known. For example a DNA encoding one form of PACE, known as furin, is disclosed i A.M.W. van den Ouweland et al., Nucl. Acids Res. .18., 664 (1990) incorporated herein by reference. A cDNA encoding a soluble for of PACE, known as PACESOL, is set forth in SEQ ID NO:5. DNA encoding other forms of PACE also exist, and any such PACE encoding DNA may be used to produce the soluble mature P-selecti ligand protein of the invention, so long as the PACE is capabl of cleaving the P-selectin ligand protein at amino acids 38-41 Preferably, a DNA encoding a soluble form of PACE is used t produce the soluble mature P-selectin ligand protein of th present invention. The DNAs encoding a soluble form of the P-selectin ligan protein and PACE, separately or together, may be operably linke to an expression control sequence such as those contained in th pMT2 or pED expression vectors discussed above, in order t produce the PACE-cleaved soluble P-selectin ligand recombinantly. Additional suitable expression control sequences are known in th art. Examples 3(C) and 3(D) below set forth methods fo producing the soluble mature P-selectin ligand protein of th invention. A number of types of cells may act as suitable host cell for expression of the P-selectin ligand protein. Suitable hos cells are capable of attaching carbohydrate side chain characteristic of functional P-selectin ligand protein. Suc capability may arise by virtue of the presence of a suitabl glycosylating enzyme within the host cell, whether naturall occurring, induced by chemical mutagenesis, or throug transfection of the host cell with a suitable expression plasmid containing a DNA sequence encoding the glycosylating enzyme. Host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primar explants, HeLa cells, mouse L cells, BHK, HL-60, U937, or Ha cells. The P-selectin ligand protein may also be produced b operably linking the isolated DNA of the invention and one o more DNAs encoding suitable glycosylating enzymes to suitabl control sequences in one or more insect expression vectors, an employing an insect expression system. Materials and methods fo baculovirus/insect cell expression systems are commerciall available in kit form from, e.g., Invitrogen, San Diego California, U.S.A. (the MaxBac® kit), and such methods are wel known in the art, as described in Summers and Smith, Texa Agricultural Experiment Station Bulletin No. 1555 (1987) incorporated herein by reference. Soluble forms of the P selectin ligand protein may also be produced in insect cell using appropriate isolated DNAs as described above. A DN encoding a form of PACE may further be co-expressed in an insec host cell to produce a PACE-cleaved form of the P-selectin ligan protein. Alternatively, it may be possible to produce the P-selecti ligand protein in lower eukaryotes such as yeast or i prokaryotes such as bacteria. Potentially suitable yeast strain include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable o expressing heterologous proteins. Potentially suitable bacteria strains include Escherichia coli, Bacillus subtilis, Salmonell typhimurium, or any bacterial strain capable of expressin heterologous proteins. If the P-selectin ligand protein is mad in yeast or bacteria, it is necessary to attach the appropriat carbohydrates to the appropriate sites on the protein moiet covalently, in order to obtain the glycosylated P-selectin ligan protein. Such covalent attachments may be accomplished usin known chemical or enzymatic methods. The P-selectin ligand protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a DN sequence encoding the P-selectin ligand protein. The P-selectin ligand protein of the invention may b prepared by culturing transformed host cells under cultur conditions necessary to express a P-selectin bindin glycoprotein. The resulting expressed glycoprotein may then b purified from culture medium or cell extracts. Soluble forms o the P-selectin ligand protein of the invention can be purifie by affinity chromatography over Lentil lectin-Sepharose® an subsequent elution with 0.5M α-methyl-mannoside. The elute soluble P-selectin ligand protein can then be further purifie and concentrated by a 0-70% ammonium sulfate precipitation step The protein is then recovered, resuspended, and further purifie by size exclusion chromatography over a TSK G4000SWχ L Alternatively, full length forms of the P-selectin ligand protei of the invention can be purified by preparing a total membran fraction from the expressing cell and extracting the membrane with a non-ionic detergent such as Triton X-100. The detergen extract can then be passed over an affinity column comprised o immobilized P-selectin, and the P-selectin ligand protein can b eluted from the column with lOmM EDTA in a buffer containing 0.1 detergent. The material eluted from the affinity column can the be dialyzed to remove EDTA and further purified over a Lenti lectin-Sepharose® affinity column, again eluting with 0.5M α methyl-mannoside. Alternatively, the P-selectin ligand protein of th invention is concentrated using a commercially available protei concentration filter, for example, an Amicon or Millipor Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such a a gel filtration medium. Alternatively, an anion exchange resi can be employed, for example, a matrix or substrate havin pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g. S-Sepharose® columns) . The purification of the P-selectin ligan protein from culture supernatant may also include one or mor column steps over such affinity resins as concanavalin A-agarose heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or b hydrophobic interaction chromatography using such resins a phenyl ether, butyl ether, or propyl ether; or by immunoaffinit chromatography. Finally, one or more reverse-phase high performance liqui chromatography (RP-HPLC) steps employing hydrophobic RP-HPL media, e.g., silica gel having pendant methyl or other aliphati groups, can be employed to further purify the P-selectin ligan protein. Some or all of the foregoing purification steps, i various combinations, can also be employed to provide substantially homogeneous isolated recombinant protein. The P selectin ligand protein thus purified is substantially free o other mammalian proteins and is defined in accordance with th present invention as "isolated P-selectin ligand protein". The isolated P-selectin ligand protein may be useful i treating conditions characterized by P-selectin mediate intercellular adhesion. Such conditions include, withou limitation, myocardial infarction, bacterial or viral infection, metastatic conditions, inflammatory disorders such as arthritis, acute respiratory distress syndrome, asthma, emphysema, delaye type hypersensitivity reaction, systemic lupus erythematosus, thermal injury such as burns or frostbite, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, multiple organ injury syndrome secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis (Sweet's syndrome), inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndrome, cytokine-induced toxicity, and the like. The isolated P-selectin ligand protein may also be useful in organ transplantation, both to prepare organs for transplantation and to quell organ transplant rejection. The isolated P-selectin ligand protein may be used to treat hemodialysis and leukophoresis patient Additionally, the isolated P-selectin ligand protein may be us as an antimetastatic agent. The isolated P-selectin liga protein may be used itself as an inhibitor of P-selectin-mediat intercellular adhesion or to design inhibitors of P-selecti mediated intercellular adhesion. The present inventio encompasses both pharmaceutical compositions containing isolate P-selectin ligand protein and therapeutic methods of treatmen or use which employ the isolated P-selectin ligand protein. The isolated P-selectin ligand protein, purified from cell or recombinantly produced, may be used as a pharmaceutica composition when combined with a pharmaceutically acceptabl carrier. Such a composition may contain, in addition to the P selectin ligand protein and carrier, diluents, fillers, salts buffers, stabilizers, solubilizers, and other materials wel known in the art. The term "pharmaceutically acceptable" mean a non-toxic material that does not interfere with th effectiveness of the biological activity of the activ ingredient(s) . The characteristics of the carrier will depen on the route of administration. The pharmaceutical compositio of the invention may also contain cytokines, lymphokines, o other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2 IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 G-CSF, Meg-CSF, stem cell factor, and erythropoietin. Th pharmaceutical composition may contain thrombolytic or anti thrombotic factors such as plasminogen activator and Factor VIII The pharmaceutical composition may further contain other anti inflammatory agents. Such additional factors and/or agents ma be included in the pharmaceutical composition to produce synergistic effect with the isolated P-selectin ligand protein, or to minimize side effects caused by the isolated P-selecti ligand protein. Conversely, the isolated P-selectin ligan protein may be included in formulations of the particula cytokine, lymphokine, other hematopoietic factor, thrombolyti or anti-thrombotic factor, or anti-inflammatory agent to minimiz side effects of the cytokine, lymphokine, other hematopoieti factor, thrombolytic or anti-thrombotic factor, or anti inflammatory agent. The pharmaceutical composition of the invention may be i the form of a liposome in which the isolated P-selectin ligan protein is combined, in addition to other pharmaceuticall acceptable carriers, with amphipathic agents such as lipids whic exist in aggregated form as micelles, insoluble monolayers liquid crystals, or lamellar layers which in aqueous solution Suitable lipids for liposomal formulation include, withou limitation, monoglycerides, diglycerides, sulfatides lysolecithin, phospholipids, saponin, bile acids, and the like Preparation of such liposomal formulations is within the leve of skill in the art, as disclosed, for example, in U.S. Paten No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No 4,837,028; and U.S. Patent No. 4,737,323, all of which ar incorporated herein by reference. As used herein, the term "therapeutically effective amount means the total amount of each active component of th pharmaceutical composition or method that is sufficient to sho a meaningful patient benefit, i.e., healing of chronic condition characterized by P-selectin-mediated cellular adhesion o increase in rate of healing of such conditions. When applied t an individual active ingredient, administered alone, the ter refers to that ingredient alone. When applied to a combination the term refers to combined amounts of the active ingredient that result in the therapeutic effect, whether administered i combination, serially or simultaneously. In practicing the method of treatment or use of the presen invention, a therapeutically effective amount of isolated P selectin ligand protein is administered to a mammal having a P selectin-mediated disease state. The isolated P-selectin ligan protein may be administered in accordance with the method of th invention either alone or in combination with other therapie such as treatments employing cytokines, lymphokines or othe hematopoietic factors. When co-administered with one or mor cytokines, lymphokines or other hematopoietic factors, th isolated P-selectin ligand protein may be administered eithe simultaneously with the cytokine(s) , lymphokine(s) , othe hematopoietic factor(s) , thrombolytic or anti-thrombotic factors or sequentially. If administered sequentially, the attendin physician will decide on the appropriate sequence o administering the isolated P-selectin ligand protein i combination with cytokine(s) , lymphokine(s) , other hematopoieti factor(s), thrombolytic or anti-thrombotic factors. Administration of the isolated P-selectin ligand protei used in the pharmaceutical composition or to practice the metho of the present invention can be carried out in a variety o conventional ways, such as oral ingestion, inhalation, o cutaneous, subcutaneous, or intravenous injection. Intravenou administration to the patient is preferred. When a therapeutically effective amount of isolated P selectin ligand protein is administered orally, the isolated P selectin ligand protein will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionall contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% isolated P-selectin ligand protein, and preferably from about 25 to 90% isolated P-selectin ligand protein. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the isolated P-selectin ligand protein and preferably from about 1 to 50% isolated P-selectin ligand protein. When a therapeutically effective amount of isolated P- selectin ligand protein is administered by intravenous, cutaneous or subcutaneous injection, the isolated P-selectin ligand protein will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to p isotonicity, stability, and the like, is within the skill in t art. A preferred pharmaceutical composition for intravenous cutaneous, or subcutaneous injection should contain, in additio to the isolated P-selectin ligand protein an isotonic vehicl such as Sodium Chloride Injection, Ringer's Injection, Dextros Injection, Dextrose and Sodium Chloride Injection, Lactate Ringer's Injection, or other vehicle as known in the art. Th pharmaceutical composition of the present invention may als contain stabilizers, preservatives, buffers, antioxidants, o other additive known to those of skill in the art. The amount of isolated P-selectin ligand protein in th pharmaceutical composition of the present invention will depen upon the nature and severity of the condition being treated, an on the nature of prior treatments which the patient ha undergone. Ultimately, the attending physician will decide th amount of isolated P-selectin ligand protein with which to trea each individual patient. Initially, the attending physician wil administer low doses of the isolated P-selectin ligand protei and observe the patient's response. Larger doses of isolated P selectin ligand protein may be administered until the optima therapeutic effect is obtained for the patient, and at that poin the dosage is not increased further. It is contemplated that th various pharmaceutical compositions used to practice the metho of the present invention should contain about 0.1 μg to about 10 mg of isolated P-selectin ligand protein per kg body weight. The duration of intravenous therapy using the pharmaceutica composition of the present invention will vary, depending on th severity of the disease being treated and the condition an potential idiosyncratic response of each individual patient. I is contemplated that the duration of each application of th isolated P-selectin ligand protein will be in the range of 12 t 24 hours of continuous intravenous administration. Ultimatel the attending physician will decide on the appropriate duratio of intravenous therapy using the pharmaceutical composition o the present invention. The isolated P-selectin ligand protein of the invention ma also be used to immunize animals to obtain polyclonal an monoclonal antibodies which specifically react with the P selectin ligand protein and which may inhibit P-selectin-mediate cellular adhesion. Such antibodies may be obtained using th entire P-selectin ligand protein as an immunogen, or by usin fragments of the P-selectin ligand protein such as the solubl mature P-selectin ligand protein. Smaller fragments of the P selectin ligand protein may also be used to immunize animals such as the fragments set forth below: amino acid 42 to amin acid 56 of SEQ ID NO:l and amino acid 127 to amino acid 138 o SEQ ID NO:l. An additional peptide immunogen comprises amin acid 238 to amino acid 248 of SEQ ID NO:l, with an alanin residue added to the amino terminus of the peptide. Anothe peptide immunogen comprises amino acid 43 to amino acid 56 of SE ID NO:l having a sulfated tyrosine in any or all of positions 46, 48 or 51. The peptide immunogens additionally may contain cysteine residue at the carboxyl terminus, and are conjugated t a hapten such as keyhole limpet hemocyanin (KLH) . Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J.Amer.Chem.Soc. .85, 2149-2154 (1963); J.L. Krstenansky, et al., FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the P-selectin ligand glycoprotein or to complex carbohydrate moieties characteristic of the P-selectin ligand glycoprotein may be useful diagnostic agents for the immunodetection of inflammatory diseases and some forms of cancer. Some cancerous cells, such as small cell lung carcinomas, may express detectable levels of the P-selectin ligand protein. This abnormal expression of the P-selectin ligand protein by cancer cells may play a role in the metastasis of these cells. Neutralizingmonoclonal antibodies binding to the P-selectin ligand glycoprotein or to complex carbohydrates characteristic of the P-selectin ligand glycoprotein may also be useful therapeutics for both inflammatory diseases and also in the treatment of some forms of cancer where abnormal expression o the P-selectin ligand protein is involved. These neutralizin monoclonal antibodies are capable of blocking the selecti mediated intercellular adherence function of the P-selecti ligand protein. By blocking the binding of the P-selectin ligan protein, the adherence of leukocytes to sites of inappropriat inflammation is either abolished or markedly reduced. In th case of cancerous cells or leukemic cells, neutralizin monoclonal antibodies against the P-selectin ligand protein ma be useful in detecting and preventing the metastatic spread o the cancerous cells which may be mediated by the P-selecti ligand protein. In addition, the monoclonal antibodies bound t these cells may target the cancerous cells for antibody-dependen cell medicated cytoxicity (ADCC) , thus helping to eliminate th cancerous cells. Human antibodies which react with the p selectin ligand protein may be produced in transgenic animal which contain human immunoglobulin encoding genes in their ger lines. Example 7 below sets forth production of a rabbi polyclonal antibody specific for P-selectin ligand protei fragments. The P-selectin ligand protein of the invention may also b used to screen for agents which are capable of binding to the P selectin ligand protein and thus may act as inhibitors of P selectin mediated intercellular adhesion. Binding assays usin a desired binding protein, immobilized or not, are well known in the art and may be used for this purpose using the P-selectin ligand protein of the invention. Appropriate screening assays may be cell-based, as in Example 3 below. Alternatively, purified protein based screening assays may be used to identify such agents. For example, P-selectin ligand protein may be immobilized in purified form on a carrier and binding to purified P-selectin may be measured in the presence and in the absence of potential inhibiting agents. A suitable binding assay may alternatively employ purified P-selectin immobilized on a carrier, with a soluble form of the P-selectin ligand protein of the invention. Any P-selectin ligand protein may be used in the screenin assays described above. For example, the full-length P-selecti ligand protein set forth in SEQ ID NO:l from amino acid 1 t amino acid 402 may be used to screen for inhibitors; or th mature P-selectin ligand protein set forth in SEQ ID NO:l fro amino acid 42 to amino acid 402 may be used to screen fo inhibitors, or the soluble mature P-selectin ligand protein se forth in SEQ ID N0:1 from amino acid 42 to amino acid 310 may b used to screen for inhibitors. Alternatively, the P-selecti ligand protein of SEQ ID NO:3 from amino acid 1 to amino aci 412, or a mature form of the P-selectin ligand protein as se forth in SEQ ID NO:3 from amino acid 42 to amino acid 412, or a soluble mature form of the P-selectin ligand protein set forth in SEQ ID NO:3 from amino acid 42 to amino acid 320 may be used to screen for inhibitors of intercellular adhesion in accordance with the present invention. In such a screening assay, a first binding mixture is formed by combining P-selectin and the P-selectin ligand protein, and the amount of binding in the first binding mixture (B 0 ) is measured. A second binding mixture is also formed by combining P-selectin, the P-selectin ligand protein, and the compound or agent to be screened, and the amount of binding in the second binding mixture (B) is measured. The amounts of binding in the first and second binding mixtures are compared, for example, by performing a B/B 0 calculation. A compound or agent is considered to be capable of inhibiting P-selectin mediated intercellular adhesion if a decrease in binding in the second binding mixture as compared to the first binding mixture is observed. The formulation and optimization of binding mixtures is within the level of skill in the art, such binding mixtures may also contain buffers and salts necessary to enhance or to optimize binding, and additional control assays may be included in the screening assay of the invention. Compounds found to reduce by at least about 10%, preferably greater than about 50% or more of the binding activity of P- selectin ligand protein to P-selectin may thus be identified and then secondarily screened in other selectin binding assays, including assays of binding to E-selectin and to L-selectin a in vivo assays. By these means compounds having inhibito activity for selectin-mediated intercellular adhesion which ma be suitable as anti-inflammatory agents may be identified. EXAMPLE 1 CLONING OF THE P-SELECTIN LIGAND PROTEIN GENE A. Construction of the HL60 cDNA library An HL60 cDNA library was constructed for expression clonin the P-selectin ligand. PolyA "1" RNA was isolated from total RN from the human promyelocytic cell line HL60 (S.J. Collins, e al., supra) using a Fast Track mRNA Isolation Kit (Invitrogen San Diego, CA) . Double stranded cDNA was synthesized from th polyA + RNA fraction and blunt-end ligated with EcoRI adaptors (5'-AATTCCGTCGACTCTAGAG-3',5'CTCTAGAGTCGACGG-3') . The cDNA wa ligated into the expression vector pMT21 (R. Kaufman et al., J Mol. Cell. Biol. 9., 946-958 (1989) that had been incubate sequentially with EcoRI endonuclease and calf intestinal alkalin phosphatase and gel purified. The ligation product wa electroporated in 2 μl aliquots into competent E. coli DH5α cell and grown in 1 ml of SOB medium (J. Sambrook et al.. Molecula Cloning: A Laboratory Manual. New York, Cold Spring Harbo Laboratory Press, pi.90 (1989)) which has been supplemented wit 10 mM MgCl 2 , 10 mM MgS0 4 , and 2 % glycerol for one hour at 37°C. In order to divide the library into smaller subsets, an aliquo from each ml of bacterial suspension was plated onto agar plate in the presence of ampicillin, and the number of colonies per m was calculated. Assuming that each colony represented one cDN clone, 600,000 clones were generated and divided into subsets o approximately 16,000 clones per pool. Each of the 38 pools were grown overnight in L-broth in the presence of ampicillin and th plasmids were purified over a CsCl gradient. B. Screening for the P-selectin liσand protein σene In the first stage,the LEC-γl binding assay of Example 4(A) was utilized to pan the HL60 cDNA library and thereby to enrich for the plasmid of interest. Six μg of each HL60 cDNA library pool was co-transfected with 2 μg of α 3/4FT gene (Example 2) into COS cells. Approximately 45 hours post-transfection, the COS cells were lifted from the plates by incubating the cells in ImM EGTA for 15 min. at 37°C, followed by scraping with cel lifters. The cells were washed twice in Hanks buffered salin solution containing ImM calcium (HBSS) . The cells wer resuspended in 4 ml of HBSS. The resuspended transfected CO cells were screened using the LEC-γl binding assay described i Example 4(A) . The plasmids from adherent COS cells were recovered from Hirts extract [B. Hirts, J. Mol. Biol., 26, 365-369 (1967)] an then electroporated into E. coli DH5α cells for amplification. The enriched population of plasmids was purified over a CsCl gradient and re-transfected along with the 3/4FT gene (Example 2) into COS cells. The transfection, screening, and plasmid amplification process was repeated for a total of three times before a pool that bound to the LEC-γl-coated plates was visually detected. The positive plasmid pool was subsequently broken down into subsets. This involved electroporating the Hirts extract from the positive pool into E. coli DH5α cells and quantitating colonies per ml as described above. Various pool sizes were produced by plating out a predetermined number of colonies on agar plates in the presence of ampicillin. Duplicate plates were prepared by performing nitrocellulose lifts and storing the filters on new agar plates. The duplicate plates served as reference plates for selecting individual or groups of colonies from any pool identified as being positive. In the second stage of cloning, COS cells were co¬ transfected with the sublibrary pools and the 3/4FT gene by the same procedure used in the initial steps of screening. Forty- eight hours post-transfection, the transfected cells were screened using the fluorescent CHO:P-selectin assay of Example 4(B). Positive pools were further subdivided, as described above, until finally individual colonies were screened and positive clones identified. Using this method, a single positive clone, pMT21:PL85, was found to encode the P-selectin ligand protein. The DNA sequence of the P-selectin ligand contained in pMT21:PL85 is set forth in SEQ ID NO:l, and the binding characteristics of the P-selectin ligand protein encodedx by pMT21:PL85 are set forth in Example 4(C) below. EXAMPLE 2 CLONING THE a 1,3/1,4 FUCOSYLTRANSFERASE GENE The α 1,3/1,4 fucosyltransferase gene (3/4FT) was clone from total human genomic DNA (Clontech Laboratories) by means o PCR. The sense oligonucleotide primer contained an Xbal site an t h e 5 ' t e rm i nu s o f t h e g e n e ( 5 ' TAGCATACGCTCTAGAGCATGGATCCCCTGGGTGCA GCCAAGC-3') , and the antisense oligonucleotide primer containe an EcoRI site and the 3'terminus of the gene (5' CCGGAATTCTCAGGTGAA CCAAGCCGC-3') . The PCR product was sequentially digested wit Xbal and EcoRI and purified by standard gel purification methods This gene was then ligated with vector pMT3Sv2ADA (R. Kaufman Methods in Enzymology, supra) that had also been sequentiall digested with Xbal and EcoRI and purified by standard ge purification methods. Competent HB101 cells (Biorad) wer transformed with this ligation product and then plated on aga plates in the presence of ampicillin. Nitrocellulose filte lifts of ampicillin-resistant transformants were probed with radiolabeled oligonucleotide (5'-AAGTATCTGTCCAGGGCTTCCAGGT-3') complementary to the nucleotide region 506-530 in the middle o the gene (J. Sambrook et al., supra) . Plasmid DNA minipreps were prepared from twelve positiv clones. The purified DNA was then digested with EcoRI and Xba to identify the correct clone with the proper size insert. Thi clone (pEA.3/4FT) was then grown up large scale and the DN isolated by CsCl density gradient banding (J. Sambrook et al., supra) . DNA sequencing confirmed the identity of the 3/4FT gene. The functionality of the gene was assessed in a cell-cell bindin assay as follows. COS-1 monkey cells [(clone M6; M. Horwitz et al., Mol. Appl. Genet., 2:147-149, (1983)] were transfected with 3/4FT using DEAE dextran followed by DMSO shock treatment and chloroquine incubation [L. Sompeyrac and K. Dana, Proc. Natl. Acad. Sci., 78:7575-7578 (1981); M. Lopata et al. , Nucleic Acids Res., 12:5707-5717, (1984); H. Luthman and G. Magnuson, Nucleic Acids Res., 11:1295-1308, (1983)]. The transfected COS cells were suspended and quantitated for binding to a CHO lin expressing E-selectin [G. Larsen et al., J. Biol. Chem 267:11104-11110, (1992)]. This assay confirmed that the CO cells transfected with 3/4FT can express the siaylated Lewis epitope on the cell surface. EXAMPLE 3 EXPRESSION OF THE P-SELECTIN LIGAND PROTEIN A. Expression of the P-selectin Ligand in LECH cells Functional P-selectin ligand was expressed in the SLe* positive Chinese hamster ovary (CHO) cell line LECH (Campbell, C. and Stanley, P.Cell 35:303-309 (1983) as follows: approximately 8 μg of plasmid containing the P-selectin ligan gene (pMT21:PL85, Example 1) was transfected into LECH cells. At 68 hours post-transfection, the cells were treated with 2. mM sodium butyrate for 4 hours. The cells were observed t induce P-selectin adhesion, as determined using the 6-CFD labele CHO:P-selectin cell binding assay (described in Example 4, section B) . In contrast, neither LECH cells alone nor LECH cells transfected with a control plasmid induced P-selecti adhesion. B. Expression of Soluble P-Selectin Ligand in COS cells COS cells were transfected with 8 μg pED.sPSL.T7 (see Example 5C) and 4 μg pEA.3/4 FT plasmid of Example 2, 8 μg pED.sPSL.T7 alone, or 8 μg plasmid vector (pMT21) and 4 μg pEA.3/4 FT gene. Forty-five hr post-transfection, the cells were rinsed twice in PBS and incubated overnight at 37°C in serum-free DMEM minus phenol red (JRH Biosciences) supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Phenylmethylsulfonyl fluoride, aprotinin and NaN 3 were added to final concentrations of ImM, 2 μg/ml and 0.02%, respectively, and the conditioned medium was centrifuged to remove all debris. For immunoprecipitation experiments, the labeled soluble P- selectin ligand protein was produced by co-transfecting COS cells with pED.sPSL.T7 and pEA.3/4 FT. At forty-five hr post transfection, the COS cells were labeled with 250 μCi/ml 35 methionine (NEN) for 5 hours and the medium was collected Expression of SPSL.T7 protein was confirmed b immunoprecipitation with anti-T7 antibodies. C. Expression of PACE-cleaved P-selectin ligand in COS Cells COS cells were co-transfected with the pED.sPSL.T7 plasmi of Example 5(C), the pEA.3/4FT cDNA of Example 2, and a plasmi containing the PACE cDNA as set forth in SEQ ID NO:5. A paralle control co-transfection was done using only the pED.sPSL.T plasmid and the pEA.3/4FT plasmid. After 45 hours, conditione medium from these transfected COS cells was coated onto plasti dishes and binding to CHO:P-selectin cells (Example 4) wa determined. An approximately two-fold increase in bound CH0:P selectin cells was observed for dishes coated with mediu containing the P-selectin ligand co-expressed with PACE, a compared with medium containing P-selectin ligand which had no been co-expressed with PACE. Amino acid sequencing of the N terminus of purified SPSL.T7 protein from the PACE co transfection showed that all of the ligand had been cleaved a the PACE consensus site (amino acids 38-41 of SEQ ID NO:l). Radiolabeling of co-transfected COS cells with 35 S-methionine an subsequent SDS-polyacrylamide gel electrophoresis and autoradiography showed that comparable quantities of the P- selectin ligand had been secreted in both co-transfections. D. Expression of the P-selectin Ligand Protein in CHO Cells A full-length form (amino acids 1-402) of the P-selectin ligand protein was expressed in the CHO(DUKX) cell line (Urlaub & Chasin, Proc. Natl. Acad. Sci. USA 77, 4216-4220 (1980)) as follows: approximately 25 μg of the pMT21:PL85 plasmid and approximately 8 μg of the pED.3/4FT (produced by restriction of PEA.3/4FT with EcoRI and Xbal and insertion of the resulting fragment into the pED plasmid) were co-transfected into CHO(DUKX) cells using the calcium phosphate method. Transfectants were selected for resistance to methotrexate. After two weeks. individual colonies were screened for SLe* expression by using conjugate of an anti SLe* antibody (CSLEX-1, U.S. 4,752,569) an sheep red blood cells (sRBC) prepared by the chromic chlorid method (Goding, J. W. , J. Immunol. Methods .10:61-66 (1976) a follows: sRBC were washed with 0.15M NaCl until the wash becam clear and then a 50% suspension of sRBC was prepared in 0.15 Nacl. One ml of 0.01% chromic chloride solution was adde dropwise while vortexing to 0.2 ml of a sRBC suspensio containing 50 μg of CSLEX-1. After incubating at 37°C for 3 minutes, 10 ml of phosphate buffered saline (PBS) solution wa added to the reaction. The conjugate was washed once befor resuspending into 10 ml of PBS. The plates containin transfectants were washed with PBS and then 3 ml of PBS and on ml of the sRBC/CSLEX-1 conjugate was added to each plate Positive colonies were red on a transilluminator and were picke into alpha medium with 10% fetal bovine serum. After two weeks colonies were subjected to stepwise amplification usin methotrexate at concentrations of 2, 10, 25, 100, 250 nM. Th stable cell line obtained was designated CD-PSGL-1 (R3.4) Expression of the P-selectin ligand protein was confirmed b immunoprecipitation studies using the polyclonal anti-P-selecti ligand protein antibody of Example 7(A) . The functionality o the P-selectin ligand protein produced by the CD-PSGL-1 (R3.4) cell line was tested by assaying the transfectants for bindin to LEC-γl as in Example 4(A) . The SPSL.T7 protein was expressed in a stable CHO-PACE lin which was already expressing the cDNA encoding PACE as set fort in SEQ ID NO:5 under adenosine deaminase selection (Kaufman, e al., PNAS (USA) 82:3136-3140 (1986)). The psPSL.T7 (25 μg) an pED.3/4FT (8 μg) plasmids were cotransfected into CHO-PACE cell using the calcium phosphate method. Transfectants were selecte for resistance to methotrexate, and individual colonies whic bound to the sRBC/CSLEX-1 conjugate were picked. After two weeks in culture, the colonies were subjected to stepwise amplification as described above. The stable cell line obtained was designated CP/PSL-T7 (R4.1). Expression of SPSL.T7 protein was confirmed by standard immunoprecipitation methods using either a T7 specific monoclonal antibody or the LEC-7I chimera of Exampl 4(A). In a similar fashion, a stable cell line expressing th mature full length form (amino acids 42-402) of the P-selecti ligand protein was obtained by co-transfection of pMT21:PL85an pED.3/4FT into the CHO-PACE line. Stable cell lines expressing the sPSL.Q protein of Exampl 5(B) and the sPSL.Fc protein of Example 5(D) were constructed a follows: plasmids pED.sPSL.Q (25 μg) or pED.sPSL.Fc (25 μg) wer cotransfected with approximately 25 μg of the pED.3/4FT plasmi described above and approximately 20 μg of a plasmid containin the PACE cDNA as set forth in SEQ ID NO:5) as well as th neomycin resistance gene into CHO(DUKX) cells using the calciu phosphate method. Transfectants were selected for resistance t methotrexate and the G418 antibiotic. Approximately two week later, individual colonies were screened for SLe* expressio using sRBC/CSLEX-l conjugate binding. The positive colonies wer picked in G418 medium at 1 mg/ml concentration. After 2-3 week in culture, cells were amplified with methotrexate in a stepwis selection. The stable cell lines obtained were designated CD sPSL.Q (R8.2) and CD-sPSL.Fc (R8.1), respectively. Th expression of sPSL.Q and sPSL.Fc protein was confirmed b standard immunoprecipitation method using the anti P-selecti ligand protein polyclonal antibody of Example 7(A) . EXAMPLE 4 ASSAYS OF P-SELECTIN-MEDIATED INTERCELLULAR ADHESION A. LEC-71 Binding Assay A DNA encoding a chimeric form of P-selectin conjugated to the Fc portion of a human IgGγl (LEC-7I) was constructed usin known methods (Aruffo et al. Cell j67, 35-44 (1991)), and stably transfected into dhfr- CHO cells (CHO DUKX) for high level production of the chimeric LEC-7I protein, which was purified for use in the binding assay set forth below. Petri dishes were coated first with a polyclonal anti-human IgG l Fc antibody and then with LEC-7I. This method orients the LEC-7I construct such that the P-selectin portion of the chimeri molecule is presented on the surface of the plates. Adhesion o HL60 cells to the oriented LEC-7I was quantitated in the presenc and absence of calcium. HL60 adhesion was shown to be calciu dependent, confirming that the chimeric molecule had retaine functional binding of P-selectin to its ligand on HL60 cells The binding of HL60 cells to oriented LEC-7I was also shown t be blocked by a neutralizing monoclonal antibody to P-selectin demonstrating the specificity of P-selectin binding. B. Fluorescent CHO-P-selectin Binding Assay The assay employed a fluorescently labeled CHO:P-selecti cell line (Larsen et al., J. Biol. Chem.167, 11104-11110 (1992) that can bind to and form clusters on the surface of COS cell that are co-transfected with the P-selectin ligand gene and th 3/4 FT gene. The CHO:P-selectin cells were suspended at 1.5 10° cells/ml in 1% fetal bovine serum in DME medium and labele by adding 6-carboxyfluorescein diacetate (6-CFD) to a fina concentration of 100 ug/ml. After incubation at 37°C for 1 minutes, the cells were washed in medium and resuspended at 1 10 5 cells/ml. Five ml of the labeled cells were added to eac washed COS transfectant-containing plate to be assayed an incubated at room temperature for 10 minutes. Nonadherent cell were removed by four washes with medium. The plates were the scanned by fluorescence microscopy for rosettes of adheren CHO:P-selectin cells. C. Quantitative adhesion assay using radioactivelv labeled CHO:P-selectin cells COS cells were co-transfected with the pMT21:PL85 plasmi of Example 1 and the pEA.3/4FT plasmid of Example 2 by the sam procedure used in the initial stages of screening. As controls, COS cells were transfected with pMT21:PL85 alone, or wit pEA.3/4FT alone, or with a similar plasmid containing no insert ("mock") . 24 hours post-transfection, the transfected cells were trypsinized and distributed into Costar 6-well tissue culture plates. CHO:P-selectin cells were labeled for 16 hours with 3 H- thymidine using known methods and preincubated at 0.5 x 10° cells/ml for 30 minutes at 4°C in α medium containing 1% BS (control) ; α medium containing 1% BSA, 5 mM EDTA and 5 mM EGT α medium containing 1% BSA and 10 μg/ml of a neutralizing ant P-selectin monoclonal antibody; and α medium containing 1% BS and a non-neutralizing anti-P-selectin monoclonal antibody. Th preincubated cells were then added to the wells containing th transfected COS cells. After a 10 minute incubation, unboun cells were removed by 4 changes of medium. The bound CHO:P selectin cells were released by trypsinization and quantified b scintillation counting. COS cells co-transfected with P-selectin ligand and th 3/4FT induced approximately 5.4-fold more binding of CHO:P selectin cells relative to COS mock cells; assay in the presenc of EGTA and EDTA reduced binding to the level of the moc transfected COS cells. Likewise, incubation with neutralizin anti-P-selectin antibody also eliminated specific binding whereas non-neutralizing antibody had no effect. In contrast the binding of CHO:P-selectin to COS cells transfected with P selectin ligand alone was not statistically different tha binding to the mock-transfected COS in both the presence o absence of EDTA and EGTA, or anti-P-selectin antibodies. Th binding of CHO:P-selectin cells to COS cells transfected with 3/ FT alone was approximately 2-fold greater than to the mock transfected COS, but was unaffected by the presence or absenc of EDTA and EGTA. EXAMPLE 5 CONSTRUCTION OF SOLUBLE P-SELECTIN LIGANDS The EcoRI adaptors used to generate the cDNA library fro HL60 cells in Example I contain an Xbal restriction site (TCTAGA) just 5' of the beginning of SEQ ID NO:l as it is located in th pMT21:PL85 plasmid. In order to generate soluble forms of th PSL, the pMT2l:PL85 plasmid was restricted with Xbal and wit Hindi (which cleaves after nucleotide 944 of SEQ ID N0:1). Th approximately 950 bp fragment thus generated, containing all o the encoded extracellular segment of the ligand up to an including the codon for valine 295, was isolated and used to generate DNAs encoding soluble forms of the P-selectin liga protein as set forth in sections A though D below. A. Construction of psPSL.OC The fragment was purified and ligated into mammali expression vector pED between the Xbal and EcoRI sites, alo with double stranded synthetic oligonucleotide DNA that recreat the codons from Asn 296 to Cys 310 and introduced a novel st codon immediately following Cys 310. The sequence of the olig is as follows: 5'-AACTACCCAGTGGGAGCACCAGACCACATCTCTGTGAAGCAGTGCTAG 5'-AATTCTAGCACTGCTTCACAGAGATGTGGTCTGGTGCTCCCACTGGGTAGTT The resulting plasmid was designated pED.sPSL.QC, and the protei expressed from the plasmid was designated sPSL.QC. B. Construction of psPSL.O The fragment was purified and ligated into the pED plasmi (Kaufman et al., 1991) between the Xbal and EcoRI sites, alon with the double stranded synthetic oligonucleotide DNA tha recreated the codons from Asn 296 to Gin 309 and introduced novel stop codon immediately following Gin 309. The sequence o the oligos is as follows: 5'-AACTACCCAGTGGGAGCACCAGACCACATCTCTGTGAAGCAGTAG 5'-AATTCTACTGCTTCACAGAGATGTGGTCTGGTGCTCCCACTGGGTAGTT The resulting plasmid was designated pED.sPSL.Q, and the protei expressed from the plasmid was designated sPSL.Q. C Construction of psPSL.T? Oligonucleotides encoding 14 amino acids including a epitope derived from the phage T7 major capsid protein wer synthesized, creating a C-terminal fusion of the epitope "tag with an additional 32 amino acids derived from the vecto sequence. Two oligonucleotides having the sequences 5'-CTAGACCCGGGATGGCATCCATGACAGGAGGACAACAAATGGTAGGCCGTAG and 5'-AATTCTACGGCCTACCCATTTGTTGTCCTCCTGTCATGGATGCCATCCCGGGT were duplexed and ligated with the large Xbal-EcoRI fragment o mammalian expression plasmid pED. The resulting plasmid, pED.T was restricted with Xbal and Smal and ligated to the 950 bp Xbal HincII fragment described above, resulting in plasmi pED.sPSL.T7. The protein resulting from expression of pED.sPSL.T7 wa designated SPSL.T7. D. Construction of Soluble P-selectin Ligand—IgGFc Chimera The plasmid DNA encoding a soluble, extracellular form o the P-selectin ligand protein fused to the Fc portion of huma immunoglobulin IgGl was constructed as follows: the mammalia expression vector pED.Fc contains sequences encoding the F region of a human IgGl with a novel linker sequence enabling th fusion of coding sequences amino terminal to the hinge region vi a unique Xbal restriction site. A three fragment ligation wa performed: pED.Fc was restricted with Xbal and gel purified i linear form. The 950 bp fragment from pMT21:PL85 describe above comprised the second fragment. The third fragmen consisted of annealed synthetic oligonucleotide DNAs having the following sequence: 5' - CTGCGGCCGCAGT 5' - CTAGACTGCGGCCGCAG The ligation products were grown as plasmid DNAs and individual clones having the correct configuration were identified by DNA sequencing. The plasmid was designated pED.PSL.Fc. The DNA coding region of the resulting soluble P-selectin ligand /Fc fusion protein is shown in SEQ ID NO:6. EXAMPLE 6 CHARACTERIZATION OF EXPRESSED P-SELECTIN LIGANDS A. Binding Characterization of Full-Length P-selectin Ligand Protein Expressed on COS Cells Co-transfection of COS cells with the pEA.3/4FT plasmid of Example 2 and the pMT21:PL85 plasmid of Example l yields COS cells which specifically bind to CHO:P-selectin cells. This binding is observed only upon co-transfection of pEA.3/4FT and pMT21:PL85; use of either plasmid alone generates COS cells which do not bind to CHO:P-selectin cells. No binding is observe between the parental CHO(DUKX) cell line which does not expres P-selectin and COS cells co-transfected with pEA.3/4FT an pMT21:PL85. The binding between the co-transfected COS cells an CHO:P-selectin cells is sensitive to chelators of divalent ion such as EDTA and EGTA, consistent with the Ca ++ dependency of P selectin mediated cellular adhesion. A neutralizing anti-P selectin monoclonal antibody blocked the binding between th CHO:P-selectin cells and the COS cells which had been co transfected with pEA.3/4FT and pMT21:PL85, while a non neutralizing anti-P-selectin monoclonal antibody had no effec on the binding. The antibody results indicate that th functional domain(s) of P-selectin are required for binding t P-selectin ligand protein expressed on the surface of COS cells. B « Electrophoretic Characterization of Full-Length P-selectin Ligand Expressed in COS Cells Detergent extracts of co-transfected COS cells were prepare as follows: 45 hours post co-transfection, approximately 1.5 10 7 cells were suspended in 5 ml of lysis buffer (lOm Piperazine-N,N'-bis[2-ethanesulfonic acid] (PIPES) pH 7.5, 10 mM KC1, 3 mM MgCl 2 , 1 mM benzamidine, 0.5 μg/ml leupeptin, 0.7 μg/ml pepstatin, 1 mM ethylmaleimide, and 1 μg/ml aprotinin) an lysed by sonication. Cellular debris was removed by low spee centrifigation (500 x g. 10 minutes) , and a membrane fractio collected by ultracentrifugation (100,000 x g, 60 min) . The hig speed membrane pellet was resuspended in an extraction buffer (10 mM 3-[N-Morpholino]propanesulfonic acid] (MOPS) pH 7.5, 0.1 NaCl, 0.02% NaN 3 , 1% Thesit® (Sigma), 1 mM benzamidine, 0.5 μg/ml leupeptin, 0.75 μg/ml pepstatin, 1 mM ethylmaleimide, and 1 μg/ml aprotinin) . Samples were then subjected to SDS polyacrylamide gel electrophoresis and transfer to nitrocellulose blots as follows: an aliquot of the detergent extract was suspended in 1% SDS loading buffer and heated for 5 minutes at 100°C before loading onto an 8-16% polyacrylamide gel (reduced) or a 6% gel (non-reduced) and electrophoresed in the Laemmli buffer system. Blots were prepared using Immobilon-P® transfer membranes. The blots were immersed in 10 mM MOPS pH 7.5, O.lM NaCl, 0.02% NaN 3 , 1 mM MgCl 2 , 1 mM CaCl 2 , and 10% non-fat milk overnight at 4°C Blots were rinsed once in the above buffer, minus the milk, an incubated in blotting buffer (10 mMMOFS pH 7.5, O.lM NaCl, 1 bovine serum albumin, 0.05% Thesit, 1 mM MgCl 2/ 1 mM CaCl 2 ) fo 30 minutes at room temperature. The blots were then probed for the P-selectin ligand a follows: 50 ng of a P-selectin/Fc chimera was pre-incubated wit 3 μCi of 125 I-Protein A in blotting buffer for 30 minutes at roo temperature. Additional excipients (e.g., EDTA, EGTA, monoclonal antibodies) could be added to the pre-incubation mixture at this point to evaluate their effects on binding of the chimera to the P-selectin ligand. The pre-incubated mixture was then incubated with the blots (prepared as above) for 60 minutes at room temperature, and the blots were subsequently washed four times with the same blotting buffer (without bovine serum albumin) , air dried, and autoradiographed at -70°C. Under non-reducing conditions, two bands were observed with this technique for membrane extracts prepared from co-transfected COS cells. The major band migrated with an estimated molecular weight of approximately 220 kD, whereas the minor band migrated with a molecular weight of approximately 110 kD. Under reducing conditions, only a single band was observed with a molecular weight of approximately 110 kD, indicating that under non- reducing conditions, the P-selectin ligand exists as a homodimer. The approximate molecular weight of the reduced monomer is greater than that predicted from the deduced amino acid sequence of the cDNA clone (45 kD) , indicating that the expressed protein undergoes extensive post-translational modification (see Example 6(C)). The specificity of the P-selectin/Fc chimera was confirmed by the observation that a nonspecific IgG, probe yielded no bands on the blots. Additionally, the binding of the P-selectin/Fc chimera to the blots was abolished by EDTA, EGTA, and a neutralizing anti-P-selectin monoclonal antibody. Specific bands on the blots were observed only from membrane extracts of COS cells co-transfected with the pEA.3/4FT and pMT21:PL85 plasmids. Membrane extracts from control transfections (pEA.3/4FT or pMT21:PL85 alone) failed to yield observable band on blots. C. Glycosylation of P-selectin Ligand Protein The presence of covalently attached carbohydrate o recombinant P-selectin ligand and its role in binding to P selectin was determined as follows: COS cells were co transfected with pED.sPSL.T7 of Example 5(C) and the pEA.3/4F plasmid of Example 2. After 48 hours, the cells were pulsed wit 35 S-methionine. 200 μl of 35 S methionine-labeled SPSL.T conditioned medium was incubated with 5 μg LEC-7I in the presenc of 2mM CaCl 2 and 1 mg/ml bovine serum albumin (BSA) . Afte rotating for 2 hours at 4°C, Protein A-Sepharose bead (Pharmacia) were added for 1 hour at 4°C, pelleted b centrifugation and washed twice in Tris buffered saline ( 20 m Tris-HCl, 150 mM NaCl pH 7.5, hereinafter TBS) containing 2m CaCl 2 and 1 mg/ml BSA. The pellets were then resuspended an treated with neuraminidase (Streptococcus pneumoniae) , O glycanase, and N-glycanase (all from Genzyme) as follows. Al glycosidase digestions were done at 37°C overnight. Fo neuraminidase digestion, the pellet was resuspended in 50 μl 2 (N-morpholino)-ethanesulfonic acid (MES) buffer, pH 6. (Calbiochem) and 0.1% SDS, heated at 95°C for 5 minutes, the pelleted. The supernatant was modified to contain 1.4% n-Octy B-D-glucopyranoside (OGP) , lOmM calcium acetate, 20 mM sodiu cacodylate and 2.5 mM PMSF, final pH 7.0 Eight μl neuraminidas was added for a final concentration of 1 unit/ml. Fo neuraminidase/O-glycanase digestion, the sample was prepared a above and along with the neuraminidase, the O-glycanase was als added to a final concentration of 0.1 unit/ml. For N-glycanas digestion, the pellet was resuspended in 54 ul MES buffer and 1% SDS, heated at 95°C for 5 minutes, then pelleted. Th supernatant was modified to contain 0.2 M sodium phosphate, 3.5% OGP, and 2.5 mM PMSF, final pH 8.5. N-glycanase was added fo a final concentration of 12 units/ml and incubated as above. The effect of glycosidase treatment on SPSL.T7 was assessed in two ways. For this, each digested protein sample was divided into two equal fractions. One fraction was precipitated with t P-selectin polyclonal antibody of Example 7(A) , to show t effect of digestion on the electrophoretic mobility. The oth fraction was precipitated with the LEC-7I chimera of Examp 4(A) , to assess the remaining P-selectin ligand binding activi after digestion. The immunoprecipitationed samples were analyz by SDS-polyacrylamide gel electrophoresis under reduci conditions and autoradiography. In the absence of glycosidase treatment, autoradiograph revealed comparable bands (with molecular weights of 110 kD) fo each precipitation. When the P-selectin ligand protein wa treated with neuraminidase, anti-P-selectin ligand polyclona antibody precipitation revealed a slight decrease in mobility consistent with removal of sialic acid residues. The amount o P-selectin ligand protein precipitated by LEC-71 wa significantly reduced after neuraminidase treatment, consisten with the role of sialic acid residues in the P-selectin/P selectin ligand interaction. When the P-selectin ligand protei was treated with both neuraminidase and O-glycanase, substantial increase in electrophoretic mobility was observe after precipitation with the anti-P-selectin ligand polyclona antibody, indicating that a number of O-linked oligosaccharid chains had been removed. However, removal of O-linke oligosaccharides from the P-selectin ligand protein may not hav been complete, since the electrophoretic mobility did no correspond to a protein with a molecular weight of 38 kD, a would be predicted from the amino acid sequence set forth in SE ID NO:l. The neuraminidase/O-glycanase digested P-selecti ligand protein bound to LEC-7I very poorly, further indicatin the role of oligosaccharides in the P-selectin/P-selectin ligan interaction. Treatment of the purified P-selectin ligand wit N-glycanase resulted in a slight increase in electrophoreti mobility, demonstrating that some of the consensus sites for N linked glycosylation are occupied. The amount of P-selecti ligand protein precipitated by LEC-7I was slightly reduced, indicating that N-linked glycosylation also contributes to th P-selectin/P-selectin ligand interaction, though not a dramatically as sialylation and O-lmked glycosylation. EXAMPLE 7 POLYCLONAL ANTIBODIES SPECIFIC FOR P-SELECTIN LIGANDS A. Polyclonal Rabbit anti-P-selectin Ligand Protein/Maltos Binding Protein Fusion Protein The anti-P-selectin ligand polyclonal antibodywas generate by immunizing rabbits with a fusion protein generated in E. coli The fusion protein consisted of the amino terminal one-third o the P-selectin ligand (amino acids 1 to 110 of SEQ ID NO:l) fuse in frame to the maltose binding protein (Maina, C. V. et al. Gene 74, 365-373 (1988); Riggs, P., in Current Protocols i Molecular Biology. F. M. Ausebel et al., Eds., Green Associates/Wiley Interscience (New York, 1990) chapter 16.6) Under conditions employed herein, the fusion protein antibod recognizes the P-selectin ligand protein. B. Polyclonal Rabbit Anti-sPSL.T7 Protein A soluble form of the invention (SPSL.T7; see example 5(C)) was purified to apparent homogeneity according to the followin scheme: COS cells were transfected with three plasmids, on encoding each of the following: SPSL.T7 (Example 5(C)), 3/4F (Example 2), and a soluble form of PACE (as set forth in SEQ I NO:5) . After 72 hours, the conditioned medium was collected an recombinant SPSL.T7 was purified as follows. Conditioned medium was diluted two fold with 50 mM MOPS, 150 mM NaCl, 0.5 mM CaCl 2 and 0.5 mM MnCl 2 , pH 7.2, and applied to column of lentil lectin-Sepharose 4B equilibrated in the sam buffer. After loading, the column was washed with the sam buffer until the optical absorbance at 280 nm dropped to a stable baseline. The column was then eluted with the same buffer which had been adjusted to 0.5 M α-methyl-mannoside and 0.3 M NaCl. Recombinant SPSL.T7 was collected over 5-15 column volumes of this elution buffer. The lentil lectin eluate was then subjected to a 0-70% ammonium sulfate precipitation by adding 472g of ammonium sulfate per liter of column eluate at 4°C. After stirring for 30 minutes, the precipitate was resuspended in minimal volume of TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) a applied to a TSK G4000SW XL gel filtration column equilibrated TBS. The flow rate on the column was 0.5 ml/min and a gua column was employed. In aliquots of < 250 μl, the resuspend ammonium sulfate pellet was injected on the column and fractio analyzed by SDS-PAGE with Western analysis. Fractions containin SPLS.T7 were pooled and then used for immunizing rabbits. Antibodies to SPSL.T7 were generated in the standard fashio by antigen priming and subsequent boosting over a 3 month period Specifically, primary immunization was performed by mixing 50 μ of SPSL.T7 (denatured by mixing in 0.1% SDS and heating for 1 minutes at 100°C) with complete Freund's adjuvant and injected a five sites subcutaneously. The second (and all subsequent boosts were performed by mixing 25 μg of SPSL.T7 (denatured b mixing in 0.1% SDS and heating for 10 minutes at 100°C) [12.5 μ for the third and subsequent boosts] with incomplete Freund' adjuvant and injecting at two sites subcutaneously (or later intramuscularly) every two weeks. Test bleeds were performe every two weeks to monitor antibody titer. When the antibod titer reached a suitable level, a larger scale bleed wa performed and a total serum fraction prepared. This polyclona antibody preparation was used to inhibit the specific binding o HL60 cells to CHO:P-selectin cells in a manner similar to tha described in Example 4. This assay employed fluorescently-labeled HL60 cell (labelled with BCECFAM; 2',7'-bis-(2-carboxymethyl)-5-(and-6) carboxyfluorescein, acetoxymethyl ester) binding to CHO cell plated on the bottom of microtiter plates. The labelled HL6 cells were pre-incubated with either sera containing polyclona antibody or with pre-immune sera for 30 minutes at 4°C. Th cells were then washed and incubated with the CHO:P-selecti cells for 10 minutes. The plates were then washed and th fluorescence read with a fluorescence microtiter plate reader. Using this assay, a 1:15 dilution of the anti-sPSL.T7 polyclona serum resulted in essentially complete inhibition of HL60 cel binding to CHO:P-selectin. Demonstrable inhibition of HL6 binding to CHO:P-selectin was still observed at antiser dilutions of 1:150. Pre-immune serum had no effect on HL60 cel binding to CHO:P-selectin. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: GENETICS INSTITUTE, INC. (ii) TITLE OF INVENTION: NOVEL P-SELECTIN LIGAND PROTEIN (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Legal Affairs (B) STREET: 87 CambridgePark Drive (C) CITY: Cambridge (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 02140 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/965,662 (B) FILING DATE: 23-OCT-1992 (C) APPLICATION NUMBER: US 08/112,608 (D) FILING DATE: 26-AUG-1993 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: McDaniels, Patricia A. (B) REGISTRATION NUMBER: 33,194 (C) REFERENCE/DOCKET NUMBER: Gl 5213B-PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 876-1210 Ext. 8405 (B) TELEFAX: (617) 876-5851 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1649 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (G) CELL TYPE: Promyelocyte (H) CELL LINE: HL60 (vii) IMMEDIATE SOURCE: (B) CLONE: pMT21:PL85 (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..59 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 60..1268 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1269..1649 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GCCACTTCTT CTGGGCCCAC GAGGCAGCTG TCCCATGCTC TGCTGAGCAC GGTGGTGCC 59 ATG CCT CTG CAA CTC CTC CTG TTG CTG ATC CTA CTG GGC CCT GGC AAC 107 Met Pro Leu Gin Leu Leu Leu Leu Leu lie Leu Leu Gly Pro Gly Asn 1 5 10 15 AGC TTG CAG CTG TGG GAC ACC TGG GCA GAT GAA GCC GAG AAA GCC TTG 155 Ser Leu Gin Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu 20 25 30 GGT CCC CTG CTT GCC CGG GAC CGG AGA CAG GCC ACC GAA TAT GAG TAC 203 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gin Ala Thr Glu Tyr Glu Tyr 35 40 45 CTA GAT TAT GAT TTC CTG CCA GAA ACG GAG CCT CCA GAA ATG CTG AGG 251 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg 50 55 60 AAC AGC ACT GAC ACC ACT CCT CTG ACT GGG CCT GGA ACC CCT GAG TCT 299 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser 65 70 75 80 ACC ACT GTG GAG CCT GCT GCA AGG CGT TCT ACT GGC CTG GAT GCA GGA 347 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly 85 90 95 GGG GCA GTC ACA GAG CTG ACC ACG GAG CTG GCC AAC ATG GGG AAC CTG 395 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu 100 105 110 TCC ACG GAT TCA GCA GCT ATG GAG ATA CAG ACC ACT CAA CCA GCA GCC 443 Ser Thr Asp Ser Ala Ala Met Glu lie Gin Thr Thr Gin Pro Ala Ala 115 120 125 ACG GAG GCA CAG ACC ACT CCA CTG GCA GCC ACA GAG GCA CAG ACA ACT 491 Thr Glu Ala Gin Thr Thr Pro Leu Ala Ala Thr Glu Ala Gin Thr Thr 130 135 140 CGA CTG ACG GCC ACG GAG GCA CAG ACC ACT CCA CTG GCA GCC ACA GAG 539 Arg Leu Thr Ala Thr Glu Ala Gin Thr Thr Pro Leu Ala Ala Thr Glu 145 150 155 160 GCA CAG ACC ACT CCA CCA GCA GCC ACG GAA GCA CAG ACC ACT CAA CCC 587 Ala Gin Thr Thr Pro Pro Ala Ala Thr Glu Ala Gin Thr Thr Gin Pro 165 170 175 ACA GGC CTG GAG GCA CAG ACC ACT GCA CCA GCA GCC ATG GAG GCA CAG 635 Thr Gly Leu Glu Ala Gin Thr Thr Ala Pro Ala Ala Met Glu Ala Gin 180 185 190 ACC ACT GCA CCA GCA GCC ATG GAA GCA CAG ACC ACT CCA CCA GCA GCC 683 Thr Thr Ala Pro Ala Ala Met Glu Ala Gin Thr Thr Pro Pro Ala Ala 195 200 205 ATG GAG GCA CAG ACC ACT CAA ACC ACA GCC ATG GAG GCA CAG ACC ACT 731 Met Glu Ala Gin Thr Thr Gin Thr Thr Ala Met Glu Ala Gin Thr Thr 210 215 220 GCA CCA GAA GCC ACG GAG GCA CAG ACC ACT CAA CCC ACA GCC ACG GAG 779 Ala Pro Glu Ala Thr Glu Ala Gin Thr Thr Gin Pro Thr Ala Thr Glu 225 230 235 240 GCA CAG ACC ACT CCA CTG GCA GCC ATG GAG GCC CTG TCC ACA GAA CCC 827 Ala Gin Thr Thr Pro Leu Ala Ala Met Glu Ala Leu Ser Thr Glu Pro 245 250 255 AGT GCC ACA GAG GCC CTG TCC ATG GAA CCT ACT ACC AAA AGA GGT CTG 875 Ser Ala Thr Glu Ala Leu Ser Met Glu Pro Thr Thr Lys Arg Gly Leu 260 265 270 TTC ATA CCC TTT TCT GTG TCC TCT GTT ACT CAC AAG GGC ATT CCC ATG 923 Phe l e Pro Phe Ser Val Ser Ser Val Thr His Lys Gly lie Pro Met 275 280 285 GCA GCC AGC AAT TTG TCC GTC AAC TAC CCA GTG GGG GCC CCA GAC CAC 971 Ala Ala Ser Asn Leu Ser Val Asn Tyr Pro Val Gly Ala Pro Asp His 290 295 300 ATC TCT GTG AAG CAG TGC CTG CTG GCC ATC CTA ATC TTG GCG CTG GTG 1019 lie Ser Val Lys Gin Cys Leu Leu Ala lie Leu lie Leu Ala Leu Val 305 310 315 320 GCC ACT ATC TTC TTC GTG TGC ACT GTG GTG CTG GCG GTC CGC CTC TCC 1067 Ala Thr He Phe Phe Val Cys Thr Val Val Leu Ala Val Arg Leu Ser 325 330 335 CGC AAG GGC CAC ATG TAC CCC GTG CGT AAT TAC TCC CCC ACC GAG ATG 1115 Arg Lys Gly His Met Tyr Pro Val Arg Asn Tyr Ser Pro Thr Glu Met 340 345 350 GTC TGC ATC TCA TCC CTG TTG CCT GAT GGG GGT GAG GGG CCC TCT GCC 1163 Val Cys He Ser Ser Leu Leu Pro Asp Gly Gly Glu Gly Pro Ser Ala 355 360 365 ACA GCC AAT GGG GGC CTG TCC AAG GCC AAG AGC CCG GGC CTG ACG CCA 1211 Thr Ala Asn Gly Gly Leu Ser Lys Ala Lys Ser Pro Gly Leu Thr Pro 370 375 380 GAG CCC AGG GAG GAC CGT GAG GGG GAT GAC CTC ACC CTG CAC AGC TTC 1259 Glu Pro Arg Glu Asp Arg Glu Gly Asp Asp Leu Thr Leu His Ser Phe 385 390 395 400 CTC CCT TAGCTCACTC TGCCATCTGT TTTGGCAAGA CCCCACCTCC ACGGGCTCTC 1315 Leu Pro CTGGGCCACC CCTGAGTGCC CAGACCCCAA TCCACAGCTC TGGGCTTCCT CGGAGACCCC 1375 TGGGGATGGG GATCTTCAGG GAAGGAACTC TGGCCACCCA AACAGGACAA GAGCAGCCTG 1435 GGGCCAAGCA GACGGGCAAG TGGAGCCACC TCTTTCCTCC CTCCGCGGAT GAAGCCCAGC 1495 CACATTTCAG CCGAGGTCCA AGGCAGGAGG CCATTTACTT GAGACAGATT CTCTCCTTTT 1555 TCCTGTCCCC CATCTTCTCT GGGTCCCTCT AACATCTCCC ATGGCTCTCC CCGCTTCTCC 1615 TGGTCACTGG AGTCTCCTCC CCATGTACCC AAGG 1649 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Pro Leu Gin Leu Leu Leu Leu Leu He Leu Leu Gly Pro Gly As 1 5 10 15 Ser Leu Gin Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Le 20 25 30 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gin Ala Thr Glu Tyr Glu Tyr 35 40 45 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg 50 55 60 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser 65 70 75 80 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly 85 90 95 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu 100 105 110 Ser Thr Asp Ser Ala Ala Met Glu He Gin Thr Thr Gin Pro Ala Ala 115 120 125 Thr Glu Ala Gin Thr Thr Pro Leu Ala Ala Thr Glu Ala Gin Thr Th 130 135 140 Arg Leu Thr Ala Thr Glu Ala Gin Thr Thr Pro Leu Ala Ala Thr Gl 145 150 155 160 Ala Gin Thr Thr Pro Pro Ala Ala Thr Glu Ala Gin Thr Thr Gin Pro 165 170 175 Thr Gly Leu Glu Ala Gin Thr Thr Ala Pro Ala Ala Met Glu Ala Gin 180 185 190 Thr Thr Ala Pro Ala Ala Met Glu Ala Gin Thr Thr Pro Pro Ala Ala 195 200 205 Met Glu Ala Gin Thr Thr Gin Thr Thr Ala Met Glu Ala Gin Thr Thr 210 215 220 Ala Pro Glu Ala Thr Glu Ala Gin Thr Thr Gin Pro Thr Ala Thr Glu 225 230 235 240 Ala Gin Thr Thr Pro Leu Ala Ala Met Glu Ala Leu Ser Thr Glu Pro 245 250 255 Ser Ala Thr Glu Ala Leu Ser Met Glu Pro Thr Thr Lys Arg Gly Leu 260 265 270 Phe He Pro Phe Ser Val Ser Ser Val Thr His Lys Gly He Pro Met 275 280 285 Ala Ala Ser Asn Leu Ser Val Asn Tyr Pro Val Gly Ala Pro Asp His 290 295 300 He Ser Val Lys Gin Cys Leu Leu Ala He Leu He Leu Ala Leu Val 305 310 315 320 Ala Thr He Phe Phe Val Cys Thr Val Val Leu Ala Val Arg Leu Ser 325 330 335 Arg Lys Gly His Met Tyr Pro Val Arg Asn Tyr Ser Pro Thr Glu Met 340 345 350 Val Cys He Ser Ser Leu Leu Pro Asp Gly Gly Glu Gly Pro Ser Ala 355 360 365 Thr Ala Asn Gly Gly Leu Ser Lys Ala Lys Ser Pro Gly Leu Thr Pro 370 375 380 Glu Pro Arg Glu Asp Arg Glu Gly Asp Asp Leu Thr Leu His Ser Phe 385 390 395 400 Leu Pro (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1239 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (synthetic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (G) CELL TYPE: placenta (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1239 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG CCT CTG CAA CTC CTC CTG TTG CTG ATC CTA CTG GGC CCT GGC AAC 48 Met Pro Leu Gin Leu Leu Leu Leu Leu He Leu Leu Gly Pro Gly Asn 1 5 10 15 AGC TTG CAG CTG TGG GAC ACC TGG GCA GAT GAA GCC GAG AAA GCC TTG 96 Ser Leu Gin Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu 20 25 30 GGT CCC CTG CTT GCC CGG GAC CGG AGA CAG GCC ACC GAA TAT GAG TAC 144 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gin Ala Thr Glu Tyr Glu Tyr 35 40 45 CTA GAT TAT GAT TTC CTG CCA GAA ACG GAG CCT CCA GAA ATG CTG AGG 192 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg 50 55 60 AAC AGC ACT GAC ACC ACT CCT CTG ACT GGG CCT GGA ACC CCT GAG TCT 240 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser 65 70 75 80 ACC ACT GTG GAG CCT GCT GCA AGG CGT TCT ACT GGC CTG GAT GCA GGA 288 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly 85 90 95 GGG GCA GTC ACA GAG CTG ACC ACG GAG CTG GCC AAC ATG GGG AAC CTG 336 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu 100 105 110 TCC ACG GAT TCA GCA GCT ATG GAG ATA CAG ACC ACT CAA CCA GCA GCC 384 Ser Thr Asp Ser Ala Ala Met Glu He Gin Thr Thr Gin Pro Ala Ala 115 120 125 ACG GAG GCA CAG ACC ACT CAA CCA GTG CCC ACG GAG GCA CAG ACC ACT 432 Thr Glu Ala Gin Thr Thr Gin Pro Val Pro Thr Glu Ala Gin Thr Thr 130 135 140 CCA CTG GCA GCC ACA GAG GCA CAG ACA ACT CGA CTG ACG GCC ACG GAG 480 Pro Leu Ala Ala Thr Glu Ala Gin Thr Thr Arg Leu Thr Ala Thr Glu 145 150 155 160 GCA CAG ACC ACT CCA CTG GCA GCC ACA GAG GCA CAG ACC ACT CCA CCA 528 Ala Gin Thr Thr Pro Leu Ala Ala Thr Glu Ala Gin Thr Thr Pro Pro 165 170 175 GCA GCC ACG GAA GCA CAG ACC ACT CAA CCC ACA GGC CTG GAG GCA CAG 576 Ala Ala Thr Glu Ala Gin Thr Thr Gin Pro Thr Gly Leu Glu Ala Gin 180 185 190 ACC ACT GCA CCA GCA GCC ATG GAG GCA CAG ACC ACT GCA CCA GCA GCC 624 Thr Thr Ala Pro Ala Ala Met Glu Ala Gin Thr Thr Ala Pro Ala Ala 195 200 205 ATG GAA GCA CAG ACC ACT CCA CCA GCA GCC ATG GAG GCA CAG ACC ACT 672 Met Glu Ala Gin Thr Thr Pro Pro Ala Ala Met Glu Ala Gin Thr Thr 210 215 220 CAA ACC ACA GCC ATG GAG GCA CAG ACC ACT GCA CCA GAA GCC ACG GAG 720 Gin Thr Thr Ala Met Glu Ala Gin Thr Thr Ala Pro Glu Ala Thr Glu 225 230 235 240 GCA CAG ACC ACT CAA CCC ACA GCC ACG GAG GCA CAG ACC ACT CCA CTG 768 Ala Gin Thr Thr Gin Pro Thr Ala Thr Glu Ala Gin Thr Thr Pro Leu 245 250 255 GCA GCC ATG GAG GCC CTG TCC ACA GAA CCC AGT GCC ACA GAG GCC CTG 816 Ala Ala Met Glu Ala Leu Ser Thr Glu Pro Ser Ala Thr Glu Ala Leu 260 265 270 TCC ATG GAA CCT ACT ACC AAA AGA GGT CTG TTC ATA CCC TTT TCT GTG 864 Ser Met Glu Pro Thr Thr Lys Arg Gly Leu Phe He Pro Phe Ser Val 275 280 285 TCC TCT GTT ACT CAC AAG GGC ATT CCC ATG GCA GCC AGC AAT TTG TCC 912 Ser Ser Val Thr His Lys Gly He Pro Met Ala Ala Ser Asn Leu Ser 290 295 300 GTC AAC TAC CCA GTG GGG GCC CCA GAC CAC ATC TCT GTG AAG CAG TGC 960 Val Asn Tyr Pro Val Gly Ala Pro Asp His He Ser Val Lys Gin Cys 305 310 315 320 CTG CTG GCC ATC CTA ATC TTG GCG CTG GTG GCC ACT ATC TTC TTC GTG 1008 Leu Leu Ala He Leu He Leu Ala Leu Val Ala Thr He Phe Phe Val 325 330 335 TGC ACT GTG GTG CTG GCG GTC CGC CTC TCC CGC AAG GGC CAC ATG TAC 1056 Cys Thr Val Val Leu Ala Val Arg Leu Ser Arg Lys Gly His Met Tyr 340 345 350 CCC GTG CGT AAT TAC TCC CCC ACC GAG ATG GTC TGC ATC TCA TCC CTG 1104 Pro Val Arg Asn Tyr Ser Pro Thr Glu Met Val Cys He Ser Ser Leu 355 360 365 TTG CCT GAT GGG GGT GAG GGG CCC TCT GCC ACA GCC AAT GGG GGC CTG 1152 Leu Pro Asp Gly Gly Glu Gly Pro Ser Ala Thr Ala Asn Gly Gly Leu 370 375 380 TCC AAG GCC AAG AGC CCG GGC CTG ACG CCA GAG CCC AGG GAG GAC CGT 1200 Ser Lys Ala Lys Ser Pro Gly Leu Thr Pro Glu Pro Arg Glu Asp Arg 385 390 395 400 GAG GGG GAT GAC CTC ACC CTG CAC AGC TTC CTC CCT TAG 1239 Glu Gly Asp Asp Leu Thr Leu His Ser Phe Leu Pro 405 410 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 412 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Pro Leu Gin Leu Leu Leu Leu Leu He Leu Leu Gly Pro Gly Asn 1 5 10 15 Ser Leu Gin Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu 20 25 30 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gin Ala Thr Glu Tyr Glu Tyr 35 40 45 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg 50 55 60 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser 65 70 75 80 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly 85 90 95 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu 100 105 110 Ser Thr Asp Ser Ala Ala Met Glu He Gin Thr Thr Gin Pro Ala Ala 115 120 125 Thr Glu Ala Gin Thr Thr Gin Pro Val Pro Thr Glu Ala Gin Thr Th 130 135 140 Pro Leu Ala Ala Thr Glu Ala Gin Thr Thr Arg Leu Thr Ala Thr Glu 145 150 155 160 Ala Gin Thr Thr Pro Leu Ala Ala Thr Glu Ala Gin Thr Thr Pro Pro 165 170 175 Ala Ala Thr Glu Ala Gin Thr Thr Gin Pro Thr Gly Leu Glu Ala Gin 180 185 190 Thr Thr Ala Pro Ala Ala Met Glu Ala Gin Thr Thr Ala Pro Ala Ala 195 200 205 Met Glu Ala Gin Thr Thr Pro Pro Ala Ala Met Glu Ala Gin Thr Thr 210 215 220 Gin Thr Thr Ala Met Glu Ala Gin Thr Thr Ala Pro Glu Ala Thr Glu 225 230 235 240 Ala Gin Thr Thr Gin Pro Thr Ala Thr Glu Ala Gin Thr Thr Pro Leu 245 250 255 Ala Ala Met Glu Ala Leu Ser Thr Glu Pro Ser Ala Thr Glu Ala Leu 260 265 270 Ser Met Glu Pro Thr Thr Lys Arg Gly Leu Phe He Pro Phe Ser Val 275 280 285 Ser Ser Val Thr His Lys Gly He Pro Met Ala Ala Ser Asn Leu Ser 290 295 300 Val Asn Tyr Pro Val Gly Ala Pro Asp His He Ser Val Lys Gin Cys 305 310 315 320 Leu Leu Ala He Leu He Leu Ala Leu Val Ala Thr He Phe Phe Val 325 330 335 Cys Thr Val Val Leu Ala Val Arg Leu Ser Arg Lys Gly His Met Tyr 340 345 350 Pro Val Arg Asn Tyr Ser Pro Thr Glu Met Val Cys He Ser Ser Leu 355 360 365 Leu Pro Asp Gly Gly Glu Gly Pro Ser Ala Thr Ala Asn Gly Gly Le 370 375 380 Ser Lys Ala Lys Ser Pro Gly Leu Thr Pro Glu Pro Arg Glu Asp Arg 385 390 395 400 Glu Gly Asp Asp Leu Thr Leu His Ser Phe Leu Pro 405 410 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2151 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (vii) IMMEDIATE SOURCE: (B) CLONE: pacesol (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATGGAGCTGA GGCCCTGGTT GCTATGGGTG GTAGCAGCAA CAGGAACCTT GGTCCTGCTA 60 GCAGCTGATG CTCAGGGCCA GAAGGTCTTC ACCAACACGT GGGCTGTGCG CATCCCTGGA 120 GGCCCAGCGG TGGCCAACAG TGTGGCACGG AAGCATGGGT TCCTCAACCT GGGCCAGATC 180 TTCGGGGACT ATTACCACTT CTGGCATCGA GGAGTGACGA AGCGGTCCCT GTCGCCTCAC 240 CGCCCGCGGC ACAGCCGGCT GCAGAGGGAG CCTCAAGTAC AGTGGCTGGA ACAGCAGGTG 300 GCAAAGCGAC GGACTAAACG GGACGTGTAC CAGGAGCCCA CAGACCCCAA GTTTCCTCAG 360 CAGTGGTACC TGTCTGGTGT CACTCAGCGG GACCTGAATG TGAAGGCGGC CTGGGCGCAG 420 GGCTACACAG GGCACGGCAT TGTGGTCTCC ATTCTGGACG ATGGCATCGA GAAGAACCAC 480 CCGGACTTGG CAGGCAATTA TGATCCTGGG GCCAGTTTTG ATGTCAATGA CCAGGACCCT 540 GACCCCCAGC CTCGGTACAC ACAGATGAAT GACAACAGGC ACGGCACACG GTGTGCGGGG 600 GAAGTGGCTG CGGTGGCCAA CAACGGTGTC TGTGGTGTAG GTGTGGCCTA CAACGCCCGC 660 ATTGGAGGGG TGCGCATGCT GGATGGCGAG GTGACAGATG CAGTGGAGGC ACGCTCGCTG 720 GGCCTGAACC CCAACCACAT CCACATCTAC AGTGCCAGCT GGGGCCCCGA GGATGACGGC 780 AAGACAGTGG ATGGGCCAGC CCGCCTCGCC GAGGAGGCCT TCTTCCGTGG GGTTAGCCAG 840 GGCCGAGGGG GGCTGGGCTC CATCTTTGTC TGGGCCTCGG GGAACGGGGG CCGGGAACAT 900 GACAGCTGCA ACTGCGACGG CTACACCAAC AGTATCTACA CGCTGTCCAT CAGCAGCGCC 960 ACGCAGTTTG GCAACGTGCC GTGGTACAGC GAGGCCTGCT CGTCCACACT GGCCACGACC 1020 TACAGCAGTG GCAACCAGAA TGAGAAGCAG ATCGTGACGA CTGACTTGCG GCAGAAGTGC 1080 ACGGAGTCTC ACACGGGCAC CTCAGCCTCT GCCCCCTTAG CAGCCGGCAT CATTGCTCTC 1140 ACCCTGGAGG CCAATAAGAA CCTCACATGG CGGGACATGC AACACCTGGT GGTACAGACC 1200 TCGAAGCCAG CCCACCTCAA TGCCAACGAC TGGGCCACCA ATGGTGTGGG CCGGAAAGTG 1260 AGCCACTCAT ATGGCTACGG GCTTTTGGAC GCAGGCGCCA TGGTGGCCCT GGCCCAGAAT 1320 TGGACCACAG TGGCCCCCCA GCGGAAGTGC ATCATCGACA TCCTCACCGA GCCCAAAGAC 1380 ATCGGGAAAC GGCTCGAGGT GCGGAAGACC GTGACCGCGT GCCTGGGCGA GCCCAACCAC 1440 ATCACTCGGC TGGAGCACGC TCAGGCGCGG CTCACCCTGT CCTATAATCG CCGTGGCGAC 1500 CTGGCCATCC ACCTGGTCAG CCCCATGGGC ACCCGCTCCA CCCTGCTGGC AGCCAGGCCA 1560 CATGACTACT CCGCAGATGG GTTTAATGAC TGGGCCTTCA TGACAACTCA TTCCTGGGAT 1620 GAGGATCCCT CTGGCGAGTG GGTCCTAGAG ATTGAAAACA CCAGCGAAGC CAACAACTAT 1680 GGGACGCTGA CCAAGTTCAC CCTCGTACTC TATGGCACCG CCCCTGAGGG GCTGCCCGTA 1740 CCTCCAGAAA GCAGTGGCTG CAAGACCCTC ACGTCCAGTC AGGCCTGTGT GGTGTGCGAG 1800 GAAGGCTTCT CCCTGCACCA GAAGAGCTGT GTCCAGCACT GCCCTCCAGG CTTCGCCCCC 1860 CAAGTCCTCG ATACGCACTA TAGCACCGAG AATGACGTGG AGACCATCCG GGCCAGCGTC 1920 TGCGCCCCCT GCCACGCCTC ATGTGCCACA TGCCAGGGGC CGGCCCTGAC AGACTGCCTC 1980 AGCTGCCCCA GCCACGCCTC CTTGGACCCT GTGGAGCAGA CTTGCTCCCG GCAAAGCCAG 2040 AGCAGCCGAG AGTCCCCGCC ACAGCAGCAG CCACCTCGGC TGCCCCCGGA GGTGGAGGCG 2100 GGGCAACGGC TGCGGGCAGG GCTGCTGCCC TCACACCTGC CTGAGTGATG A 2151 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1591 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (Vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (Vii) IMMEDIATE SOURCE: (B) CLONE: SPSL.FC (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATGCCTCTGC AACTCCTCCT GTTGCTGATC CTACTGGGCC CTGGCAACAG CTTGCAGCTG 60 TGGGACACCT GGGCAGATGA AGCCGAGAAA GCCTTGGGTC CCCTGCTTGC CCGGGACCGG 120 AGACAGGCCA CCGAATATGA GTACCTAGAT TATGATTTCC TGCCAGAAAC GGAGCCTCCA 180 GAAATGCTGA GGAACAGCAC TGACACCACT CCTCTGACTG GGCCTGGAAC CCCTGAGTCT 240 ACCACTGTGG AGCCTGCTGC AAGGCGTTCT ACTGGCCTGG ATGCAGGAGG GGCAGTCACA 300 GAGCTGACCA CGGAGCTGGC CAACATGGGG AACCTGTCCA CGGATTCAGC AGCTATGGAG 360 ATACAGACCA CTCAACCAGC AGCCACGGAG GCACAGACCA CTCCACTGGC AGCCACAGAG 420 GCACAGACAA CTCGACTGAC GGCCACGGAG GCACAGACCA CTCCACTGGC AGCCACAGAG 480 GCACAGACCA CTCCACCAGC AGCCACGGAA GCACAGACCA CTCAACCCAC AGGCCTGGAG 540 GCACAGACCA CTGCACCAGC AGCCATGGAG GCACAGACCA CTGCACCAGC AGCCATGGAA 600 GCACAGACCA CTCCACCAGC AGCCATGGAG GCACAGACCA CTCAAACCAC AGCCATGGAG 660 GCACAGACCA CTGCACCAGA AGCCACGGAG GCACAGACCA CTCAACCCAC AGCCACGGAG 720 GCACAGACCA CTCCACTGGC AGCCATGGAG GCCCTGTCCA CAGAACCCAG TGCCACAGAG 780 GCCCTGTCCA TGGAACCTAC TACCAAAAGA GGTCTGTTCA TACCCTTTTC TGTGTCCTCT 840 GTTACTCACA AGGGCATTCC CATGGCAGCC AGCAATTTGT CCGTCCTGCG GCCGCAGTCT 900 AGAGACAAAA CTCACACATG CCCACCGTGC CCAGCACCTG AACTCCTGGG GGGACCGTCA 960 GTCTTCCTCT TCCCCCCAAA ACCCAAGGAC ACCCTCATGA TCTCCCGGAC CCCTGAGGTC 1020 ACATGCGTGG TGGTGGACGT GAGCCACGAA GACCCTGAGG TCAAGTTCAA CTGGTACGTG 1080 GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG AGGAGCAGTA CAACAGCACG 1140 TACCGTGTGG TCAGCGTCCT CACCGTCCTG CACCAGGACT GGCTGAATGG CAAGGAGTAC 1200 AAGTGCAAGG TCTCCAACAA AGCCCTCCCA GTCCCCATCG AGAAAACCAT CTCCAAAGCC 1260 AAAGGGCAGC CCCGAGAACC ACAGGTGTAC ACCCTGCCCC CATCCCGGGA GGAGATGACC 1320 AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT ATCCCAGCGA CATCGCCGTG 1380 GAGTGGGAGA GCAATGGGCA GCCGGAGAAC AACTACAAGA CCACGCCTCC CGTGCTGGAC 1440 TCCGACGGCT CCTTCTTCCT CTATAGCAAG CTCACCGTGG ACAAGAGCAG GTGGCAGCAG 1500 GGGAACGTCT TCTCATGCTC CGTGATGCAT GAGGCTCTGC ACAACCACTA CACGCAGAAG 1560 AGCCTCTCCC TGTCCCCGGG TAAATAG 1591

Claims: CLAIMS 1. A composition comprising an isolated DNA sequence encodi a P-selectin ligand protein, said protein being characterized the amino acid sequence set forth in SEQ ID NO:l from amino ac 1 to amino acid 402. 2. A composition comprising an isolated DNA sequence encodi a soluble P-selectin ligand protein, said protein bei characterized by the amino acid sequence set forth in SEQ ID NO from amino acid 1 to amino acid 310. 3. A composition comprising an isolated DNA sequence encodi a mature P-selectin ligand protein, said protein bei characterized by the amino acid sequence set forth in SEQ ID NO: from amino acid 42 to amino acid 402. 4. A composition comprising an isolated DNA sequence encodi a soluble mature P-selectin ligand protein, said protein bei characterized by the amino acid sequence set forth in SEQ ID NO: from amino acid 42 to amino acid 310. 5. A composition comprising an isolated DNA sequence encodin a P-selectin ligand protein, said protein being characterized b the amino acid sequence set forth in SEQ ID NO:3. 6. An isolated DNA sequence capable of hybridizing unde stringent conditions to the DNA sequence of any one of claims 1 2, 3, 4 or 5. 7. The DNA sequence of any one of claims 1, 2, 3, 4, 5 or operably linked to an expression control sequence. 8. A host cell transformed with the DNA of claim 7. 9. The host cell of claim 8, comprising a mammalian cell. 10. A process for producing a P-selectin ligand protein, whi comprises: (a) culturing the host cell of claim 8 or claim 9 in suitable culture medium; and (b) purifying the P-selectin ligand protein from t culture medium. 11. A process for producing a soluble mature P-selectin liga protein which comprises: (a) co-transforming a host cell with the DNA sequence claim 4, a DNA sequence encoding an (αl,3/αl, fucosyltransferase, and a DNA sequence encoding a paired bas amino acid converting enzyme, each of said DNA sequences bei operably linked to an expression control sequence; (b) culturing the host cell in a suitable culture mediu and (c) purifying the soluble mature P-selectin ligand prote from the culture medium. 12. A composition comprising a P-selectin ligand prote characterized by the amino acid sequence set forth in SEQ ID N0: from amino acid 1 to amino acid 402, said protein bei substantially free from other mammalian proteins. 13. A composition comprising a P-selectin ligand prote characterized by the amino acid sequence set forth in SEQ ID N0: from amino acid 42 to amino acid 310, said protein bei substantially free from other mammalian proteins. 14. The composition of claim 13, further comprising pharmaceutically acceptable carrier. 15. A composition comprising a protein characterized by th amino acid sequence set forth in SEQ ID NO:3. 16. A composition comprising an antibody which specificall reacts with the P-selectin ligand protein of claim 12. 17. A composition comprising an antibody which specificall reacts with the P-selectin ligand protein of claim 13. 18. A composition comprising an antibody which specificall reacts with the protein of claim 15. 19. A method of identifying an inhibitor of P-selectin-mediate intercellular adhesion which comprises (a) combining a P-selectin protein with a P-selectin ligan protein characterized by an amino acid sequence selected from th group consisting of the amino acid sequence set forth in SEQ I N0:1 from amino acid 1 to amino acid 402, the amino acid sequenc set forth in SEQ ID N0:1 from amino acid 42 to amino acid 402 the amino acid sequence set forth in SEQ ID NO:l from amino aci 42 to amino acid 310, and the amino acid sequence set forth i SEQ ID NO:3, said combination forming a first binding mixture; (b) measuring the amount of binding between the P-selecti protein and the P-selectin ligand protein in the first bindin mixture; (c) combining a compound with the P-selectin protein an the P-selectin ligand protein to form a second binding mixture; (d) measuring the amount of binding in the second bindin mixture; and (e) comparing the amount of binding in the first bindin mixture with the amount of binding in the second binding mixture; wherein the compound is capable of inhibiting P-selectin-mediate intercellular adhesion when a decrease in the amount of bindin of the second binding mixture occurs. 20. A method of treating an inflammatory disease which comprises administering a therapeutically effective amount of the composition of claim 14 to a mammal.

Inventors: CHANG XIAO-JIA, LARSEN GLENN R, SAKO DIANNE S, VELDMAN GEERTRUIDA M, CHANG, XIAO-JIA, LARSEN, GLENN, R., SAKO, DIANNE, S., VELDMAN, GEERTRUIDA, M.
Applicants: GENETICS INST, GENETICS INSTITUTE, INC.
Application year: 1993
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P1, A61P3, A61P5, A61P9, A61P11, A61P13, A61P17, A61P19, A61P29, A61P31, A61P35, A61P37, A61P43, C07H21, C07K14, C07K16, C07K19, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1, G01N33